[STUDY_ID_REMOVED] ¬†
¬†
Study¬†ID:¬†652‚Äê205¬†
¬†
Title:  PERSEUS: ¬†A¬†Phase¬†2¬†Proof¬†of¬†Concept¬†Study¬†Investigating ¬†the¬†Preliminary ¬†Efficacy¬†and¬†Safety¬†of¬†
Cenicriviroc ¬†in¬†Adult¬†Subjects¬†with¬†Primary¬†Sclerosing¬† Cholangitis ¬†(PSC)¬†
¬†
¬†
Protocol¬†Amendment ¬†3¬†Date:¬†14¬†June¬†2016¬†
Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 1 of 82 
Amendment 3  
 
 
CONFIDENTIAL    14 June2016   
 
 
 
  Title: PERSEUS: A Phase 2 Proof of Concept Study Investigating 
the Preliminary Efficacy and Safety of Cenicriviroc in Adult Subjects with Primary Sclerosing Cholangitis (PSC)  
  Protocol Number:  652-[ADDRESS_81832]:  Cenicriviroc Mesylate (CVC) 
  Phase of Study:  Phase 2 
  Sponsor:  Tobira Therapeutics, Inc.  
 [ADDRESS_81833] 
 South San Francisco, CA [ZIP_CODE] 
 [LOCATION_002] of America
  
      Date of Protocol:  19 November 2015 Date of Amendment 1. 1:  29 December 2015 
Date of Amendment 2:   06 April 2016 
Date of Amendment 3:   14 June 2016 
  
 
 
 
The information in this document is privileged and confidential. No part of this information may be duplicated, 
referenced, or transmitted in any form or by [CONTACT_61076] (electronic, mechanical, photocopy, recording, or otherwise) 
without the prior written consent of Tobira Therapeutics.  
  

7RELUD7KHUDSHXWLFV,QF &HQLFULYLURF
&OLQLFDO6WXG\3URWRFRO  3DJHRI$PHQGPHQW
&21),'(17,$/  -XQH
(0(5*(1&<&217$&76
,QHPHUJHQF\VLWXDWLRQVWKHLQYHVWLJDWRUVKRXOGFRQWDFWWKHPH GLFDOPRQLWRULQGLFDWHG
EHORZ
3ULPDU\&RQWDFW  






 
 
 



 


6HFRQGDU\&RQWDFW 




 


 





7RELUD7KHUDSHXWLFV,QF &HQLFULYLURF
&OLQLFDO6WXG\3URWRFRO  3DJHRI$PHQGPHQW
&21),'(17,$/  -XQH
7$%/(2)&217(176
 (0(5*(1&<& 217$&76 
 7$%/(2)& 217(176 
 /LVWRI,Q7H[W7DEOHV 
 /LVWRI,Q7H[W)LJXUHV 
 /,672)$%%5 (9,$7,216 
 6<1236,6  
 ,1752'8&7,21  
 3ULPDU\6FOHURVLQJ&KRODQJLWLV   
 5ROHRI&&5DQG&&5DQG7KHLU/LJDQGVLQ36&   
 1RQFOLQLFDO6WXGLHVZLWK&9&   
 &OLQLFDO6WXGLHVZLWK&9&   
  3KDVH6WXGLHV   
  3KDVH6WXGLHVLQ+,9,QIHFWHG6XEMHFWV   
 2YHUDOO6X[COMPANY_003]U\R I&9&$FWLYLW\   
 6WXG\5DWLRQDOH   
 'RVH5DWLRQDOH   
 678'<2%-(&7,9(6(1'32, 176$1'(9$/ 8$7,216 
 ,19(67,*$7,2 1$/3/$1 
 2YHUDOO6WXG\'HVLJQDQG3ODQ   
678'<3238/ $7,21 
 1XPEHURI6XEMHFWV 
 ,QFOXVLRQ&ULWHULD 
 ([FOXVLRQ&ULWHULD 
 75($70(1 76  
 7UHDWPHQWV$GPLQLVWHUHG 
 6WXG\'UXJ   
  ,QYHVWLJDWLRQDO3URGXFW   
  3DFNDJLQJDQG/DEHOLQJ   
  6WRUDJH   
  6WXG\'UXJ'LVSHQVLQJDQG&ROOHFWLRQ   
  ,QYHVWLJDWLRQDO3URGXFW$FFRXQWDELOLW\   
  6WXG\'UXJ$GPLQLVWUDWLRQ   
 3ULRUDQG&RQFRPLWDQW7KHUDS\   
 $GGLWLRQDO5HVWULFWLRQVDQG3UHFDXWLRQV   
 7UHDWPHQW$GKHUHQFH   
 678'<352 &('85( 6 
  6FUHHQLQJ9LVLW 
  %DVHOLQH9LVLW'D\ 
7RELUD7KHUDSHXWLFV,QF &HQLFULYLURF
&OLQLFDO6WXG\3URWRFRO  3DJHRI$PHQGPHQW
&21),'(17,$/  -XQH  2Q7UHDWPHQW(YDOXDWLRQV DW:HHNVDQG'D\V 
DQG   
  :HHN)ROORZXS:HHN'D\ 
  (DUO\'LVFRQWLQXDWLRQ9LVLW   
  0LVVHG6FKHGXOHG9LVLWV 
  &ULWHULDIRU'LVFRQWLQXDWLRQRI6WXG\7UHDWPHQW 
 678'<$66(660 (176 
  'HPRJUDSKLFDQG2WKHU3UHWUHDWPHQW$VVHVVPHQWV   
  $VVHVVPHQWVRI(IILFDF\ 
  $VVHVVPHQWVRI3KD UPDFRNLQHWLFV 
  $VVHVVPHQWVRI6DIHW\ 
  $GYHUVH(YHQWVDQG6HULRXV$GYHUVH(YHQWV 
  /DERUDWRU\$VVHVVPHQWV 
  9LWDO6LJQV   
  (OHFWURFDUGLRJUDP   
  3K\VLFDO([DPLQDWLRQ   
  7R[LFLW\0DQDJHPHQW   
  %LRPDUNHU$QDO\VLV   
  $VVHVVPHQWVRI0HGLFDWLRQ$GKHUHQFH   
 67$7,67,&6  
  6DPSOH6L]HDQG3RZHU 
  *HQHUDO&RQVLGHUDWLRQV 
  $QDO\VLV3RSXODWLRQV 
  +DQGOLQJRI0LVVLQJ'DWD 
  6XEMHFW5HSODFHPHQW 
  6XEMHFW'LVSRVLWLRQ 
  (IILFDF\  
  (IILFDF\(QGSRLQW 
  0HWKRGVRI$QDO\VLVIRU3ULPDU\DQG6HFRQGDU\(IILFDF\(QGSRLQW V  
  6DIHW\   
  6DIHW\(QGSRLQWV   
  0HWKRGVRI$QDO\VLVIRU6DIHW\(QGSRLQWV   
  ,QWHULP$QDO\VLV   
 48$/,7<&[ZIP_CODE]/$ 1'48$/,7< $6685$1&(  
  6SRQVRU$XGLWV 
  ,QVSHFWLRQE\5HJXODWRU\$XWKRULWLHV 
 (7+,&6$1'3527(&7,212 )+80$168%-(&76 
  &RPSOLDQFH6WDWHPHQW 
  ,QVWLWXWLRQDO5HYLHZ%RDUG,QGHSHQGHQW(WKLFV&RPPLWWHH 
  ,QIRUPHG&RQVHQW   
  6XEMHFW&RQILGHQWLDOLW\   
7RELUD7KHUDSHXWLFV,QF &HQLFULYLURF
&OLQLFDO6WXG\3URWRFRO  3DJHRI$PHQGPHQW
&21),'(17,$/  -XQH  6WXG\&RQGXFW 
  6WXG\'LVFRQWLQXDWLRQ 
 '$7$+$1'/,1*$1'5 (&25'. ((3,1* 
  'DWD0DQDJHPHQW5HVSRQVLELOLWLHV 
  'DWD+DQGOLQJDQG5HFRUG.HHSLQJ 
  'DWD&ROOHFWLRQDQG5HWULHYDO   
  5HFRUGV5HWHQWLRQ 
  6WXG\0RQLWRULQJDQG$FFHVVWR6RXUFH'RFXPHQWV 
 38%/,&$7,2132/,&< 
 5()(5( 1&(6  
 6321625¬∂66,* 1$785(3 $*( 
 ,19(67,*$725¬∂66 ,*1$785(3 $*( 
 $33(1', &(6  
  6FKHGXOHRI$VVHVVPHQWV 
  1DWLRQDO&DQFHU,QVWLWXWH&RPPR Q7HUPLQRORJ\&ULWHULDIRU$GYHU VH
(YHQWV1&, &7&$( 
  ,QIRUPDWLRQRQ&RQWUDFHSWLRQ(IIHFWLYHQHVV   
  'LVDOORZHG0HGLFDWLRQV 
  &OLQLFDO/DERUDWRU\7HVWV   



Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-[ADDRESS_81834] of In -Text Figures  
Figure 7-1 Study Design Schematic  ........................................................................................... 25 
 
  
7RELUD7KHUDSHXWLFV,QF &HQLFULYLURF
&OLQLFDO6WXG\3URWRFRO  3DJHRI$PHQGPHQW
&21),'(17,$/  -XQH
/,672)$%%5(9,$7,216
$EEUHYLDWLRQ 'HILQLWLRQ

$'/ DFWLYLWLHVRIGDLO\OLYLQJ
$( DGYHUVHHYHQW$/3 DONDOLQHSKRVSKDWDVH$/7 DODQLQHDPLQRWUDQVIHUDVH

$'5 DGYHUVHGUXJUHDFWLRQ
$67 DVSDUWDWHDPLQRWUDQVIHUDVH$8& DUHDXQGHUWKHFRQFHQWUDWLRQWLPHFXUYH






&5) FDVHUHSRUWIRUP&
PD[ PD[LPXPSODVPDFRQFHQWUDWLRQ

&5$ FOLQLFDOUHVHDUFKDVVRFLDWH&9& FHQLFULYLURF



(&* HOHFWURFDUGLRJUDP


)'$ )RRGDQG'UXJ$GPLQLVWUDWLRQ
 


*&3 *RRG&OLQLFDO3UDFWLFH

*33 *RRG3XEOLFDWLRQ3UDFWLFH


Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-[ADDRESS_81835]  
ITT intention to treat  
  
  
  
  
  
MedDRA  Medical Dictionary for Regulatory Activities  
  
MRCP magnetic resonance cholangiopancreatography  
  
  
  
  
NCI CTCAE  National Cancer Institute Common Terminology Criteria for Adverse Events  
  
  
  
  
  
  
  
PK pharmacokinetic(s)  
PoC proof of concept  
PP per protocol  

Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 9 of 82 
Amendment 3  
 
 
CONFIDENTIAL    14 June2016  Abbreviation  Definition  
  
PSC primary sclerosing cholangitis  
QD once daily (quaque die)  
  
REB Research Ethics Board  
  
SAE serious adverse event  
  
  
SOC System Organ Class  
SOP standard operating procedures  
S[LOCATION_003]R suspected unexpected serious adverse reaction  
T1/[ADDRESS_81836] upper limit of normal  
US [LOCATION_002]  
UV Ultraviolet 
  

7RELUD7KHUDSHXWLFV,QF &HQLFULYLURF
&OLQLFDO6WXG\3URWRFRO  3DJHRI$PHQGPHQW
&21),'(17,$/  -XQH
6<1236,6
7LWOH 3(56(86$3KDVH3URRIRI&RQFHSW6WXG\,QYHVWLJDWLQJW KH3UHOLPLQDU\
(IILFDF\DQG6DIHW\RI&HQLFULYLURFLQ$GXOW6XEMHFWVZLWK3ULP DU\6FOHURVLQJ
&KRODQJLWLV36&
&OLQLFDO3KDVH 
,QGLFDWLRQ 7UHDWPHQWRI36&
2EMHFWLYHV  3ULPDU\2EMHFWLYH
x(YDOXDWHHIIHFWVRIFHQLFULYLURF&9&RQVHUXPDONDOLQHSKRVSK DWDVH
$/3RYHUZHHNVRIWUHDWPHQWLQDGXOWVXEMHFWVZLWK36&
6HFRQGDU\2EMHFWLYHV
x7RHYDOXDWHWKHVDIHW\DQGWROHUDELOLW\RI&9&RYHUZHHNVLQ DGXOW
VXEMHFWVZLWK36&
6WXG\'HVLJQ 7KLVLVDVLQJOHDUPRSHQODEHOSURRIRIFRQFHSW 3R&VWXG\RI&9&LQDGXOW
VXEMHFWVZLWK36&7KHPDLQREMHFWLYHRIWKLV3R&VWXG\LVWR DVVHVVFKDQJHVLQ
$/3ERWKLQGLYLGXDOO\DQGDVDJURXSRYHUZHHNVRIWUHDWPHQ WZLWK&9&
$QLQIRUPHGFRQVHQWIRUP,&)ZLOOEHVLJQHGSULRUWRDQ\VFUH HQLQJDFWLYLWLHV
6FUHHQLQJZLOORFFXUZLWKLQZHHNVEHIRUHWKH%DVHOLQH9LVLW 'D\$WWKH
6FUHHQLQJYLVLWVXEMHFWVZLOOXQGHUJRDOOHOLJLELOLW\HYDOXDWL RQVSHUWKHVFKHGXOH
RIDVVHVVPHQWV6XEMHFWVZKRPHHWDOOWKHHOLJLELOLW\FULWHULD ZLOOEHVFKHGXOHG
IRUD%DVHOLQHYLVLW'D\DQGHQUROOHGLQWKHVWXG\7KHILU VWGRVHRI&9&ZLOO
EHJLYHQRQVLWHDWWKH%DVHOLQHYLVLW6XEMHFWVZLOOUHWXUQW RWKHVWXG\VLWHIRU
RQWUHDWPHQWHYDOXDWLRQVDW:HHNVDQG$SSUR[LP DWHO\ZHHNV
DIWHUWKHODVWGRVHRIVWXG\GUXJ:HHNVXEMHFWVZLOOXQGH UJRIROORZXS
HYDOXDWLRQV6XEMHFWVZKRGLVFRQWLQXHVWXG\GUXJSULRUWRFRPSO HWLRQRI
ZHHNVRIWUHDWPHQWZLOOEHUHTXLUHGWRUHWXUQWRWKHFOLQLFIRU DQ(DUO\
'LVFRQWLQXDWLRQ9LVLW
7UHDWPHQW'XUDWLRQ ZHHNV
1XPEHURI6XEMHFWV $SSUR[LPDWHO\VXEMHFWVLQWRWDODOORIZ KRPZLOOEHWUHDWHGZLWKRSHQODEHO
&9&,IDVXEMHFWGLVFRQWLQXHVIURPWKHVWXG\IRUDQ\UHDVRQRW KHUWKDQVDIHW\D
UHSODFHPHQWVXEMHFWZLOOEHFRQVLGHUHG
1XPEHURI6WXG\&HQWHUV $SSUR[LPDWHO\FHQWHUVLQ&DQDGDDQG WKH8QLWHG6WDWHV
7DUJHW3RSXODWLRQ $GXOWVXEMHFWVZLWKFOLQLFDOO\GLDJQRVHG36&
,QFOXVLRQ&ULWHULD  $GXOWPDOHDQGIHPDOHVXEMHFWVDJHG\HDUVZLWKFKURQLFFK ROHVWDWLF
OLYHUGLVHDVHIRUDWOHDVWPRQWKV
&OLQLFDOGLDJQRVLVRI36&DVHYLGHQWE\FKURQLFFKROHVWDVLVRI PRUHWKDQVL[
PRQWKVGXUDWLRQZLWKHLWKHUDFRQVLVWHQWPDJQHWLFUHVRQDQFHFKRODQJLRSDQFUHDWRJUDSK\05&3HQGRVFRSLFUHWURJUDGHFKRODQJLRSDQFUHDWRJUDSK\(5&3VKRZLQJVFOHURVLQJFKRODQJLWLV RUD
OLYHUELRSV\WDNHQDWDQ\WLPHFRQVLVWHQWZLWK36&LQWKHDEVHQ FHRID
GRFXPHQWHGDOWHUQDWLYHHWLRORJ\IRUVFOHURVLQJFKRODQJLWLV,I GLDJQRVLVRI
36&ZDVPDGHE\KLVWRORJ\DORQHLWPXVWUHTXLUHWKHSUHVHQFHR IILEUR
REOLWHUDWLYHOHVLRQVLHRQLRQVNLQOHVLRQV
6XEMHFWVZLWKRUZLWKRXW,QIOD[COMPANY_003]WRU\%RZHO'LVHDVH,%'DUHD OORZHG
,IVXEMHFWKDV,%'GRFXPHQWHGHYLGHQFHRI,%'HLWKHUE\SULRU HQGRVFRS\
RULQSUHYLRXVPHGLFDOUHFRUGVIRU¬ïPRQWKV,QDGGLWLRQVXE MHFWVZLOOEH
UHTXLUHGWRHQWHUWKHVWXG\ZLWKD3DUWLDO0D\R5LVNVFRUHRI 
LQFOXVLYHO\
Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 11 of 82 
Amendment 3  
 
 
CONFIDENTIAL    14 June2016  4. In subjects receiving treatment with ursodeoxycholic ac id (UDCA), therapy 
must be stable for at least 3 months, and at a dose not greater than 20 mg/kg/day  
5. Serum ALP ‚â•1.5 √ó upper limit of normal ( ULN) 
6.  
 
 
 
 
 
 
7. Ability to understand and sign a written informed consent form (ICF)  
8. Subjects receiving allowed concomitant medications need to be on stabl e 
therapy for 28 days prior to the Baseline Visit (see Section  9.[ADDRESS_81837] of 
restricted med ications), with the exception of UDCA in which subjects  
need to be on stable therapy for ‚â• 3 months  
Exclusion Criteria  1. Presence of documented secondary sclerosing cholangitis  (such as ischemic 
cholangitis, recurrent pancreatitis, intraductal stone disease, severe bacterial 
cholangitis, surgical or blunt abdom inal trauma, recurrent pyogenic 
cholangitis, choledocholithiasis, toxic slerosing cholangitis due to chemical 
agents, or any other cause of secondary sclerosing cholangitis) o n prior 
clinical investigations  
2. Small duct PSC  
3. Presence of percutaneous drain or bile duct stent  
4. History of cholangiocarcinoma or high clinical suspi[INVESTIGATOR_75463] 1 year  by [CONTACT_75473]/ERCP or clinical judgement  
5. Ascending cholangitis within 60 days prior to Screening  
6. Alcohol consumption greater than 21 units/week for mal es or 14 units/week 
for females (one unit of alcohol is ¬Ω pi[INVESTIGATOR_43924] [285  mL], 1 glass of spi[INVESTIGATOR_2120] 
[25 mL] or 1 glass of wine [125 mL])  
7. Prior or planned liver transplantation  
8. Presence of alternative causes of chronic liver disease, including alcoholic liver disease, nonalcoholic steatohepatitis, primary biliary cirrhosis, 
autoimmune hepatitis  
9. History of cirrhosis and/or hepatic impairment (Child -Pugh classes A, B 
and C) and/or hepatic  decompensation including ascites, encephalopathy or 
variceal bleeding . Subjects who show evidence of significant worsening of 
hepatic function will be excluded  
10. Subjects with  evidence of cirrhosis, as determined by [CONTACT_75474] (TE; e.g., FibroScan
¬Æ) values of ‚â• 13.[ADDRESS_81838] 
90 days requiring intensif ication of therapy beyond Baseline treatment. 
Subjects with stable mild to moderate IBD, who are on treatment, are allowed provided they are stable for 3 months with 5- amino salicylic acid 
drugs or Azathioprine  (allowed dose of azathioprine is 50 -200 mg/da y)  
12. Use of oral prednisolone >  10 mg/day, biologics and /or hospi[INVESTIGATOR_75464] 90 d ays are disallowed   

Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 12 of 82 
Amendment 3  
 
 
CONFIDENTIAL    14 June2016  13. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT); 
above the allowed cut -offs, as determined by [CONTACT_75475] : 
‚Ä¢ AST > 200 IU/L males and females  
‚Ä¢ ALT: males > 250 IU/L and females > 200 IU/L 
14. Total Bilirubin and Direct Bilirubin; above the allowed cut -offs, as 
determined  by [CONTACT_75475]:  
‚Ä¢ Total Bilirubin  > 2.0 mg/dL  
‚Ä¢ Direct Bilirubin  > 0.8 mg/dL  
15. International normalized ratio  (INR) > 1.3 in the absence of anticoagulants.  
16. Immunoglobulin G4 (IgG4) > 4 √ó ULN at Screening  or evidence of IgG4 -
related sclerosing cholangiti s 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
34. Any
 other clinically significant disorders or prior therapy that, in the 
opi[INVESTIGATOR_871], would make the subject unsuitable for the study 
or unable to comply with the dosing and protocol requirements  
Test Article(s)  CVC 150 mg tablet 
Dosage and 
Administration  CVC 150 mg, administered orally once daily and taken every morning wi th 
food  
Placebo There is no placebo group in this study  
Study Procedures/  
Frequency  Screening will occur within 6 weeks before the Baseline Visit (Day 1).  Eligible 
subjects will be seen at Baseline (Day 1), Week 4 , Week 8, Week 12, Week  16, 
and Week 24.  A safety follow -up visit will be conducted at Week 28 ¬±  3 days 

Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 13 of 82 
Amendment 3  
 
 
CONFIDENTIAL    14 June2016  (i.e., [ADDRESS_81839] intake of study medication) or at the time of early 
termination (if applicable). On visit days, subjects will be need to  come into the 
clinic fasting. Blood samples will be collected prior to dosing.  Subjects will be 
required to bring in study medication on the days of clinic visits and dosing will 
be conducted on site with a morning snack .   
Study procedures include:  
‚Ä¢ The informed consent will be reviewed and signed at  the Screening 1 v isit, 
as well as all eligibility assessments, per the schedule of evaluations  
‚Ä¢ IgG Total, IgG 1 and IgG4 will be collected at Baseline, and Week 24 
(IgG4 will also be collected at Screening)   
‚Ä¢ Clinical laboratory tests will be measured at Screening , Baseline  and each 
study visit: clinical chemistries, hemato logy, liver parameters  including 
ALP, bilirubin, serum albumin, serum bile acids , gamma-glutamyl 
transferase (GGT), ALT and AST 
‚Ä¢ Partial Mayo Risk scoring for assessment of IBD will be conducted at 
Baseline and at each visit  
‚Ä¢ Transient elastography  will be assessed once during the Screening period 
(between Screening  to Baseline) and at Week 24 
‚Ä¢  
  
 
  
   
‚Ä¢ Ser
um samples will be collected and stored for future analysis for 
biomarkers of interest at Baseline, Weeks  12 and 24  
‚Ä¢ Plasma pharmacokinetic ( PK) samples will be drawn pre-dose and post-
dose at Baseline  and at Weeks  12, and 24 
‚Ä¢ Weight will be measured at Screening, Baseline and Weeks 12 and 24; 
height will be measured only at Screening  
‚Ä¢ Complete or symptom directed p hysical examinations and laboratory 
analyses will be performed at each visit  
‚Ä¢ Electrocardiograms  will be performed at Baseline and at Weeks 12 and 24  
‚Ä¢ Adverse events and concomitant medications will be assessed at each visit  
Efficacy Evaluation  The primary endpoint for this study is the percent change from Baseline through 
Week 24 in serum alkaline phosphatase  
 
  
  
 
  
Safety Evaluation  Safety endpoints:  
‚Ä¢ Evaluate the safety and tolerability of CVC through 24 weeks  of treatment 
in adult subjects with PSC  
‚Ä¢ Evaluate the proportion of subjects with a treatment -emergent AE or a 
clinically significant laboratory abnormality (overall and of any given 
type)  

Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 14 of 82 
Amendment 3  
 
 
CONFIDENTIAL    14 June2016  ‚Ä¢ Evaluate the proportion of subjects who discontinue due to an AE  
Other Exploratory Evaluation  
  
 
   
  
 
  
  
Statistical Analysis  This is a single arm open label study in adult subjects with PSC. Descriptive 
statistical methods will be used to summarize data from this study. Displays of treatment -related efficacy and safety profiles for each patient and overall will be 
summarized.  
Efficacy Analysis Percent changes in  ALP from Baseline will be summarized using descriptive 
statistics for the respective pre -treatment and on -treatment visits.  A repeated 
measures mixed model will be fit to the data for all pre -treatment and on -
treatment  visits, and this model will include explanatory variables for visits and 
Baseline; and it will have compound symmetry as the covariance structure. Through this model, 95% confidence intervals will be produced for the mean percent change at each visit. Als o, a comparison of pre -treatment change per 
week with on -treatment change per week will be made through an estimate 
specification and the corresponding 95% confidence interval. Descriptive 
comparisons will be made with historical data where UDCA was admini stered 
and/or with the natural history of the disease , as appropriate.  
Safety Analysis Clinical laboratory and safety data will be summarized using descriptive analysis. 
Sample Size Each patient will serve as their own control when observing ALP relative to 
Baseline.  
 
 
 
 
 
 
  

Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 15 of 82 
Amendment 3  
 
 
CONFIDENTIAL    14 June2016   
 
 
 
 
 
 
 
 
   
 
 
  
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 

Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 16 of 82 
Amendment 3  
 
 
CONFIDENTIAL    14 June2016   
 
   
  
 
 
 
 
 
  
 
 
  
 
 
 
 
 
  
 
 
 
 
  
 
  
 
 
 
 
 
  
 
 
 
 
  
 
  
  
 
 
 

Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 17 of 82 
Amendment 3  
 
 
CONFIDENTIAL    14 June2016   
  
  
 
 
 
  
  
 
 
 
  
 
  
  
 
 
  
   
 
 
 
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 

Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 18 of 82 
Amendment 3  
 
 
CONFIDENTIAL    14 June2016   
 
 
 
 
 
 
 
 
 
 
  
  
  
 
 
  
5 1 P s 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 19 of 82 
Amendment 3  
 
 
CONFIDENTIAL    14 June2016   
  
 
 
 
 
 
 
 
 
 
 
  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
5 2 P s 
 
 
 
 
 
 
 

Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 20 of 82 
Amendment 3  
 
 
CONFIDENTIAL    14 June2016   
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 

Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 21 of 82 
Amendment 3  
 
 
CONFIDENTIAL    14 June2016   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
  
  
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 

Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 22 of 82 
Amendment 3  
 
 
CONFIDENTIAL    14 June2016   
  
  
 
 
 
 
 
 
 
 
 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
  
 
 
 

Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 23 of 82 
Amendment 3  
 
 
CONFIDENTIAL    14 June2016   
 
 
  
 
 
 
 
 
  
  
 
 
 
 
  
 
 
 
 
 
 
  
 
 
  
 
 

7RELUD7KHUDSHXWLFV,QF &HQLFULYLURF
&OLQLFDO6WXG\3URWRFRO  3DJHRI$PHQGPHQW
&21),'(17,$/  -XQH
678'<2%-(&7,9(6(1'3 2,176$1'(9$/8$7,216
6WXG\2EMHFWLYHV
x(YDOXDWHHIIHFWVRI&9&RQVHUXP$/3RYHUZHHNVRIWUHDWPHQW LQDGXOWVXEMHFWV
ZLWK36&
x7RHYDOXDWHWKHVDIHW\DQGWRO HUDELOLW\RI&9&RYHUZHHNVLQ DGXOWVXEMHFWVZLWK
36&
3ULPDU\(QGSRLQW
x7KHSULPDU\HQGSRLQWIRUWKLVVWXG\LVWKHSHUFHQWFKDQJHIURP %DVHOLQHWKURXJK
:HHNLQVHUXPDONDOLQHSKRVSKDWDVH

 
 
 

6DIHW\(YDOXDWLRQV
x(YDOXDWHWKHVDIHW\DQGWROHUDELOLW\RI&9&WKURXJKZHHNVRI WUHDWPHQWLQDGXOW
VXEMHFWVZLWK36&
x(YDOXDWHWKHSURSRUWLRQRIVXEMHFWVZLWKDWUHDWPHQWHPHUJHQW$ (RUDFOLQLFDOO\
VLJQLILFDQWODERUDWRU\DEQRUPDOLW\RYHUDOODQGRIDQ\JLYHQW\ SH
x(YDOXDWHWKHSURSRUWLRQRIVXEMHFWVZKRGLVFRQWLQXHGXHWRDQ$ (



 

 
 

7RELUD7KHUDSHXWLFV,QF &HQLFULYLURF
&OLQLFDO6WXG\3URWRFRO  3DJHRI$PHQGPHQW
&21),'(17,$/  -XQH
,19(67,*$7,21$/3/$1
 2YHUDOO6WXG\'HVLJQDQG3ODQ
7KLVLVD3KDVHVLQJOHDUPRSHQODEHOSURRIRIFRQFHSWVWX G\RI&9&LQDSSUR[LPDWHO\
DGXOWVXEMHFWVZLWK36& 

6FUHHQLQJZLOORFFXUZLWKLQZHHNVEHIRUHWKH%DVHOLQH9LVLW6 XEMHFWVZLOOUHYLHZWKH,&)
DQGSURYLGHZULWWHQFRQVHQWEHIRUH DQ\VFUHHQLQJSURFHGXUHVWDN LQJSODFH$IWHUFRPSOHWLQJ
6FUHHQLQJYLVLWHOLJLEOHVXEMHFWVFDQEHVFKHGXOHGIRUVWXG\H QUROOPHQW$WWKH%DVHOLQH
9LVLWVXEMHFWVZKRKDYHPHWDOOWKHHOLJLELOLW\FULWHULDZLOO EHHQUROOHGLQWKHVWXG\DQGEHJLQ
WUHDWPHQWZLWK&9&6XEMHFWVZLOOUHWXUQWRWKHVWXG\VLWHIRU RQWUHDWPHQWHYDOXDWLRQVDW
:HHNVDQG$SSUR[LPDWHO\ZHHNVDIWHUWKHODVW GRVHRIVWXG\GUXJ:HHN
VXEMHFWVZLOOXQGHUJRIROORZXSHYDOXDWLRQV6XEMHFWVZKR GLVFRQWLQXHVWXG\GUXJSULRU
WRFRPSOHWLRQRIZHHNVRIWUH DWPHQWZLOOEHUHTXLUHGWRUHWX UQWRWKHFOLQLFIRUDQ(DUO\
'LVFRQWLQXDWLRQ9LVLW
7KHVWXG\GHVLJQLVLOOXVWUDWHGLQ )LJXUH
)LJXUH 6WXG\'HVLJQ6FKHPDWLF










6FUHHQ
 '
ZN
'
ZN
'
ZN
'
ZN
'
ZN
'
ZN
'
ZN
)ROORZXS
6FUHHQLQJ
x$GXOWVXEMHFWVZLWK36&
x6HUXP$/3¬ïWLPHV
8/1
x&RQILUPHGGLDJQRVLVRI
,%'VWDEOH
x([FOXVLRQRIDOWHUQDWLYH
FDXVHVRI OLYHUGLVHDVH
x([FOXVLRQRIFLU[LOCATION_006]RVLV
VHHIXOOHOLJLELOLW\FULWHULD
(QGSRLQWV
3ULPDU\
&KDQJHIURPEDVHOLQHLQ
VHUXP$/3WKURXJK:HHN
2WKHUDQDO\VHV
x3URSRUWLRQRISDWLHQWVZKR
DFKLHYH$/3QRUPDOL]DWLRQ
[8/1RU
GHFUHDVHLQ$/3
x+HSDWLFELRFKHPLVWULHV
x6DIHW\WROHUDELOLW\
1 
&9&PJ8SWR:HHNV
7RELUD7KHUDSHXWLFV,QF &HQLFULYLURF
&OLQLFDO6WXG\3URWRFRO  3DJHRI$PHQGPHQW
&21),'(17,$/  -XQH
678'<3238/$7,21
 1XPEHURI6XEMHFWV
$SSUR[LPDWHO\VXEMHFWVDUHSOD QQHGIRUHQUROOPHQW(OLJLEOH DGXOWSDWLHQWVZLWK36&ZLOO
EHWUHDWHGIRUZHHNVZLWK&9&
 ,QFOXVLRQ&ULWHULD
)RUDVXEMHFWWREHHOLJLEOHIR USDUWLFLSDWLRQLQWKLVVWXG\ DOORIWKHIROORZLQJFULWHULDPXVW
DSSO\
$GXOWPDOHDQGIHPDOHVXEMHFWV DJHG\HDUVZLWKFKURQLFFK ROHVWDWLFOLYHUGLVHDVH
IRUDWOHDVWPRQWKV
&OLQLFDOGLDJQRVLVRI36&DVHYLG HQWE\FKURQLFFKROHVWDVLVRI PRUHWKDQVL[PRQWKV
GXUDWLRQZLWKHLWKHUDFRQVLVWHQW PDJQHWLFUHVRQDQFHFKRODQJLRS DQFUHDWRJUDSK\05&3
HQGRVFRSLFUHWURJUDGHFKRODQJLRSD QFUHDWRJUDSK\(5&3VKRZLQJ VFOHURVLQJ
FKRODQJLWLVRUDOLYHUELRSV\WDN HQDWDQ\WLPHFRQVLVWHQWZLW K36&LQWKHDEVHQFHRID
GRFXPHQWHGDOWHUQDWLYHHWLRORJ\IRUVFOHURVLQJFKRODQJLWLV,I GLDJQRVLVRI36&ZDVPDGH
E\KLVWRORJ\DORQHLWPXVWUHTXL UHWKHSUHVHQFHRIILEURREOLW HUDWLYHOHVLRQVLHRQLRQ
VNLQOHVLRQV
 6XEMHFWVZLWKRUZLWKRXW,QIOD[COMPANY_003]WRU\%RZHO'LVHDVH,%'DUH DOORZHG,IVXEMHFWKDV
,%'GRFXPHQWHGHYLGHQFHRI,%' HLWKHUE\SULRUHQGRVFRS\RULQ SUHYLRXVPHGLFDO
UHFRUGVIRU¬ïPRQWKV,QDGG LWLRQVXEMHFWVZLOOEHUHTXLUHG WRHQWHUWKHVWXG\ZLWKD
3DUWLDO0D\R5LVNVFRUH RILQFOXVLYHO\
,QVXEMHFWVUHFHLYLQJWUHDWPHQWZ LWK8'&$WKHUDS\PXVWEHVWDE OHIRUDWOHDVWPRQWKV
DQGDWDGRVHQRWJUHDWHUWKDQPJNJGD\
6HUXP$/3¬ï√Æ8/1





$ELOLW\WRXQGHUVWDQGDQGVLJQDZ ULWWHQLQIRUPHGFRQVHQWIRUP ,&)
6XEMHFWVUHFHLYLQJDOORZHGFRQF RPLWDQWPHGLFDWLRQVQHHGWREHR QVWDEOHWKHUDS\IRU
GD\VSULRUWRWKH%DVHOLQH9LVLWVHH 6HFWLRQ IRUOLVWRIUHVWULF WHGPHGVZLWKWKH
H[FHSWLRQRI8'&$LQZ KLFKVXEMHFWVQHHGW REHRQVWDEOHWKHUDS \IRU¬ïPRQWKV
Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-[ADDRESS_81840] will not be eligible for participation in this study if any of the following criteria 
apply. 
1. Presence of documented secondary sclerosing cholangitis (such as ischemic cholangitis, 
recurrent pancreatitis, intraductal stone disease, severe bacterial cholangitis, surgical or blunt abdominal trauma, recurrent pyogenic cholangitis, choledocholithiasis, toxic slerosing cholangitis due to chemical agents, or any other cause of seco ndary sclerosing 
cholangitis)  on prior clinical investigations 
2. Small duct PSC  
3. Presence of percutaneous drain or bile duct stent 
4. History of cholangiocarcinoma or high clinical suspi[INVESTIGATOR_75463] 1 year by [CONTACT_75473]/ERCP or clinical judgement
 
5. Ascending cholangitis within 60 days prior to Screening 
6. Alcohol consumption greater than 21 units/week for males or 14 units/week for females (one unit of alcohol is ¬Ω pi[INVESTIGATOR_43924] [285 mL], 1 glass of spi[INVESTIGATOR_2120] [25 mL] or 1 glass of 
wine [125 mL]) 
7. Prior or planned liver transplantation 
8. Presence of alternative causes of chronic liver disease, including alcoholic liver disease, 
nonalcoholic steatohepatitis, primary biliary cirrhosis, autoimmune hepatitis  
9. History of cirrhosis and/or hepatic impairment (Child -Pugh classes A, B and C) and/or 
hepatic decompensation including ascites, encephalopathy or variceal bleeding.
 Subjects 
who show evidence of significant worsening of hepatic function will be excluded   
10. Subjects with  evidence of cirrhosis, as determ ined by [CONTACT_75476] (TE; 
e.g., FibroScan¬Æ) values of ‚â• 13.[ADDRESS_81841] 90  days requiring 
intensification of therapy beyond Baseline treatment. Subjects with stable mild to 
moderate IBD, who are on treatment, are allowed provided they are stable for 3 months with 5-amino salicylic acid drugs or Azathioprine (allowed dose of azathioprine is 50-200 
mg/day) 
12. Use of oral prednisolone > 10 mg/day, biologics and/or hospi[INVESTIGATOR_75465] 90 days are disallowed  
13. Aspartate aminotran sferase (AST) and alanine aminotransferase (ALT) ; above the 
allowed cut -offs, as determined by [CONTACT_75475] : 
Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 28 of 82 
Amendment 3  
 
 
CONFIDENTIAL    14 June2016  ‚Ä¢ AST > 200 IU/L males and females  
‚Ä¢ ALT males  > 250 IU/L and females  > 200 IU/L  
14. Total Bilirubin  and Direct Bilirubin; above the allowed cut-offs, as determined by [CONTACT_75477] :  
‚Ä¢ Total Bilirubin  > 2.0 mg/dL   
‚Ä¢ Direct Bilirubin  > 0.8 mg/dL   
15. International normalized ratio  (INR) > 1.3 in the absence of anticoagulants. 
16. Immunoglobulin G4 (IgG4) > 4 √ó ULN at Screening or  evidence of IgG4 -related 
sclerosing cholangitis  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-[ADDRESS_81842] unsuitable for the study or unable to comply with 
the dosing and protocol requirements 
 
  

7RELUD7KHUDSHXWLFV,QF &HQLFULYLURF
&OLQLFDO6WXG\3URWRFRO  3DJHRI$PHQGPHQW
&21),'(17,$/  -XQH
75($70(176
 7UHDWPHQWV$GPLQLVWHUHG
$OOHOLJLEOHVXEMHFWVZLOOUHFHL YHPJ&9&Q GDLO\IRU ZHHNV&9&VKRXOGEH
WDNHQHYHU\PRUQLQJZLWKIRRG
 6WXG\'UXJ
 ,QYHVWLJDWLRQDO3URGXFW
&KHPLFDO1DPH


*HQHULF1DPH &HQLFULYLURFPHV\ODWH$EEUHYLDWHG1DPH &9&/DERUDWRU\'HVLJQDWLRQ 7UDGH1DPH 1RWDSSOLFDEOH



 3DFNDJLQJDQG/DEHOLQJ
7KHVWXG\PHGLFDWLRQZLOOEHV XSSOLHGDVGHVFULEHGDERYHE\7 RELUDDQGZLOOEHSDFNDJHG
LQKLJKGHQVLW\SRO\HWK\OHQHERWWOHVFRQWDLQLQJWDEOHWVSHU ERWWOHZLWKSRO\HVWHUFRLOVLOLFD
JHOGHVLFFDQWDQGLQGXFWLRQVHDOHG
$OOODEHOVIRU&9&ZLOOPHHWDOO DSSOLFDEOHUHTXLUHPHQWVRIWKH 8QLWHG6WDWHV86)RRGDQG
'UXJ$GPLQLVWUDWLRQ)'$D QG$QQH[RI*RRG0DQXIDFWXULQJ3U DFWLFHVDQGRUDOOORFDO
UHJXODWLRQVDVDSSOLFDEOH
 6WRUDJH
$OOVWXG\PHGLFDWLRQVKRXOGEHV WRUHGDWFRQWUROOHGURRPWHPSHU DWXUH 
ZLWKWUDQVLHQWH[FXUVLRQVSHUPLWWHGWR &9&WDEOHWVZLOOFRQWLQ XHWREH
PRQLWRUHGIRUVWDELOLW\DW UHFRPPHQGHG
VWRUDJHFRQGLWLRQV
 6WXG\'UXJ'LVSHQVLQJDQG&ROOHFWLRQ
6WXG\PHGLFDWLRQ&9&ZLOOEH VXSSOLHGLQDERWWOHFRQWDLQLQJ WDEOHWVIRUHDFKVXEMHFW
ZKLFKLVVXIILFLHQWIRUGD\VGRVLQJ6WXG\GUXJERWWOHVZLOO EHDVVLJQHGE\VLWHSKDUPDFLVW
RUGHVLJQDWHGVLWHSHUVRQQHOWRV WXG\VLWHSHUVRQQHOVXEMHFWVD W%DVHOLQH:HHN:HHN
:HHNDQG:HHN$WWKHZHH NYLVLWERWWOHVZLOOEHJLY HQDVWKHQH[WVWXG\YLVLWLV
:HHN6XEMHFWVZLOOEHLQVWUXFWH GWRWDNHWDEOHWRIPHGLFD WLRQHDFKGD\LQWKHPRUQLQJ
Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-[ADDRESS_81843] Accountability 
Responsibility for drug accountability at the study site rests with the investigator; however, 
the investigator may assign some of the drug accountability duties to an appropriate pharmacist or designee. Inventory and accountability records must be maintained and must be readily available for inspection by [CONTACT_941] s tudy monitor and are open to inspection at any 
time by [CONTACT_75478].  
The investigator or designee will be expected to collect and retain all used, unused, and partially used containers of study medication. The investigator or desig nee must maintain 
records that document the following: 
‚Ä¢ Study medication delivery to the study site  
‚Ä¢ Inventory at the site  
‚Ä¢ Storage conditions  
‚Ä¢ Use by [CONTACT_6992], including tablet counts from each supply dispensed 
‚Ä¢ Return of study medications to the investigator or designee 
‚Ä¢ Destruction of returned and residual containers 
These records should include dates, quantities, batch/serial numbers (if available), and the unique code numbers (if available) assigned to the study medication and study subjects. 
The study medication must be used only in accordance with the protocol. The investigator 
will also maintain records adequately documenting that the subjects were provided the study medication specified.  
Completed accountability records will be archived by [CONTACT_779]. S tudy monitors will check 
drug accountability records and verify destruction of empty containers. 
The investigator or designee will oversee destruction of any empty containers and residual 
study drug according to institutional standard operating procedures (SOPs). In the absence of an institutional SOP, the clinical research associate (CRA) will be responsible for ensuring that the drug is sent to an appropriate drug destruction facility. The CRA will verify drug accountability records and destruction at regular intervals throughout the study. A certificate of destruction will be provided to the CRA for all destroyed drug. 
9.2.[ADDRESS_81844] any unused medication. 
9.3 Prior and Concomitant Therapy 
All medications (or treatments) other than study drug taken or received by [CONTACT_75479] 4- Week Follow-up visit will be considered 
concomitant medications (or treatments). All concomitant medications and treatments must be recorded in the case report form ( CRF). Any prior medication received within [ADDRESS_81845]‚Äôs medical condition during t he trial will also be recorded in the 
CRF.  
Subjects will be allowed to continue their usual standard- of-care medications that are not 
specifically excluded by [CONTACT_760] . Required dose modifications of medications not 
excluded by [CONTACT_75480]. 
The detailed list of disallowed study medications and the list of medications that are allowed but with specific restrictions are provided in Appendix 20.4.  
The following classes of medications are disallowed during the study: 
  
  
  
  
 
  
 
  
 
 
 
 
 
 
 
 

Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 33 of 82 
Amendment 3  
 
 
CONFIDENTIAL    14 June2016   
  
In 
instances where a disallowed medication is initiated prior to discussion with the medical 
monitor and/or Sponsor, the investigator must notify Tobira as soon as he/she is aware of the 
use of the excluded medication to discuss the subject's continued participation in the study. 
Medications that are commonly us ed for IBD  or for PSC symptoms are listed below . The 
detailed list of disallowed study medications and the list of medications that are allowed but 
with specific restrictions are provided in Appendix 20.4.  

Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 34 of 82 
Amendment 3  
 
CONFIDENTIAL    14 June2016  9.4 Addit
ional Restrictions and Precautions  
Subjects should refrain from strenuous physical activity (e.g., weight lifting, strenuous yard 
work, intensive exercise workouts) for [ADDRESS_81846] been reported in completed clinical 
studies, previous nonclinical studies indicate d that CVC and/or its metabolites have an 

7RELUD7KHUDSHXWLFV,QF &HQLFULYLURF
&OLQLFDO6WXG\3URWRFRO  3DJHRI$PHQGPHQW
&21),'(17,$/  -XQHDIILQLW\IRUPHODQLQ7KHUHIRUH DGGLWLRQDOVWXGLHVZHUHFRQGXF WHGZLWKUHVXOWVLQGLFDWLQJWKDW
&9&GLGQRWGHPRQVWUDWHSKRWRWR[ LFSRWHQWLDOLQQHXWUDOUHGXSW DNHSKRWRWR[LFLW\LQ%$/%F
7PRXVHILEUREODVWV$VDPHDV XUHRIFDXWLRQVXEMHFWVVKRXOG EHDGYLVHGWRDYRLGXQGXH
GLUHFWXOWUDYLROHW89H[SRVXU HIURPQDWXUDOVXQOLJKWRUWDQQL QJEHGV7KHVHPHDVXUHV
LQFOXGHZHDULQJVXQSURWHFWLYH FORWKLQJDQGVXQJODVVHVDQGXVLQ JD89$DQG89%
FRPELQDWLRQVXQVFUHHQVXQSURW HFWLRQIDFWRUDWOHDVW
 7UHDWPHQW$GKHUHQFH
6XEMHFWVZLOOEULQJDOORIWKHLUVWXG\VXSSOLHGSLOOERWWOHVWR HYHU\FOLQLFYLV LWDQGFOLQLFVWDII
ZLOODVVHVVDGKHUHQFHEDVHGRQWKH QXPEHURIUHPDLQLQJSLOOVOH VVDQ\RYHUDJHSURYLGHGWR
FRYHUWKHYLVLWZLQGRZ6XEMHFWV ZKRPLVVGRVHVPXVWEHFRXQVHO HGRQWKHLPSRUWDQFHRI
DGKHULQJWRWKHLUGDLO\GRVLQJVFKHGXOH
678'<352&('85(6
6WXG\SURFHGXUHVDUHVX[COMPANY_003]UL]H GDFURVVDOOVWXG\YLVLWVZLWKLQ WKH6FKHGXOHRI$VVHVVPHQWV
7DEOH 
6XEMHFWVVKRXOGUHIUDLQIURPVWUHQXRXVSK\VLFDODFWLYLW\HJ ZHLJKWOLIWLQJVWUHQXRXV\DUG
ZRUNLQWHQVLYHH[HUFLVHZRU NRXWVIRUKRXUVSULRUWRVWXG\ YLVLWVDQGODERUDWRU\
HYDOXDWLRQV
)RU,%'VXEMHFWVRQO\(OLJLEOH VXEMHFWVZLOOEHUHTXLUHGWRFR PSOHWHDGLDU\ GDLO\WRDVVHVV
VWRROIUHTXHQF\DQGEORRGLQWKHVW RRO3DUWLDO0D\R5LVNVFRUH GDLO\,QDGGLWLRQWKHGLDU\
ZLOOLQFOXGHDTXHVWL RQUHJDUGLQJDEGRPLQDO SDLQLQRUGHUWRDV VHVVLIWKHVXEMHFWGHYHORSV
DQ\VLJQLILFDQWLQFUHDVHLQDEGR PLQDOSDLQ,IDVXEMHFWH[FHH GVD3DUWLDO0D\R5LVNVFRUHRI
DWDQ\WLPHE\LQYHVWLJDWRUDVVHVVPHQWRISDWLHQWGLDU\DVZ HOODVVXEMHFWHYDOXDWLRQWKHQ
WKHVXEMHFWZLOOEHUHHYDOXDWHGI RUKLVRUKHU,%'DWWKHFOLQL FDOUHVHDUFKVLWH6KRXOGVXEMHFWV
H[SHULHQFHDQLQFUHDVHLQDEGR PLQDOSDLQVWRROIUHTXHQF\RUEO RRGLQWKHLUVWRROEHWZHHQ
YLVLWVWKH\ZLOOEHLQVWUXFWH GWRFRQWDFWWKHVLWHLPPHGLDWHO\ IRUFOLQLFDODVVHVVPHQWIRUWKHLU
,%'
7KHSULQFLSDOLQYHVWLJDWRURUGH OHJDWHZLOOEHL QVWUXFWHGWRLQ TXLUHDERXWDEGRPLQDOSDLQDW
HDFKVWXG\YLVLW$VZLWKDOOD GYHUVHHYHQWVDQ\DEGRPLQDOSDL QZLOOEHDVVHVVHGI RUVHYHULW\
DQGFDXVDOLW\E\WKHLQYHVWLJ DWRULQWKHH&5)SHU6HFWLRQ 
6FUHHQLQJ9LVLW
3ULRUWRDQ\FOLQLFDOSURFHGXUHVDQGHYDOXDWLRQVZULWWHQVLJQH GLQIRUPHGFRQVHQWPXVWEH
REWDLQHG6FUHHQLQJLVWRRFFXU DSSUR[LPDWHO\ZHHNVEHIRUHWK H%DVHOLQHYLVLWVHH
6HFWLRQ
6XEMHFWVZKRGRQRWPHHWDOOHOLJLE LOLW\FULWHULDDW6FUHHQLQJ ZLOOEHDOORZHGWRUHVFUHHQRQFH
+RZHYHULIDVXEMHFWIDLOV WRPHHWHOLJLELOLW\FULWHULDXSRQU HVFUHHQKHRUVKHZLOOUHPDLQ
LQHOLJLEOHIRUWKHVWXG\
$W6FUHHQLQJ9LVLWWKHIROORZL QJ6FUHHQLQJSURFHGXUHVDQGDVVH VVPHQWVVKRXOGEH
FRQGXFWHG
 
Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 36 of 82 
Amendment 3  
 
 
CONFIDENTIAL    14 June2016     
  
  
 
 
  
  
  
  
  
  
  
 
  
   
  
 
  
  
  
 
  
  
  
  
  
  
   
10.2
 Baseline Visit (Day 1) 
Subjects who have signed the ICF and meet all the eligibility criteria (see Sections  8.2 and 
8.3) will be enrolled in the study.  If subjects are deemed eligible once result s from the 
Screening visit are received, Baseline visit can take place immediately or approximately 
within 6 weeks after the Screening  visit. 

Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 37 of 82 
Amendment 3  
 
 
CONFIDENTIAL    14 June2016   
  
 
  
   
  
  
  
 
  
  
  
  
  
  
 
  
  
  
  
  
 
  
   
   
  
  
 
  
  
 

Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 38 of 82 
Amendment 3  
 
 
CONFIDENTIAL    14 June2016   
 
 
 
 
   
 
 
  
 
  
  
 
  
  
 
  
   
  
  
 
 
 
  
  
  
 
  
   
  
  
  
 

Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 39 of 82 
Amendment 3  
 
 
CONFIDENTIAL    14 June2016    
    
10.4 4-W
eek Follow-up (Week 28, Day 196) 
Subjects will undergo follow-up evaluations approximately [ADDRESS_81847] dose of 
study drug (Week 28). Subjects who discontinue study drug prior to completion of [ADDRESS_81848] dose of study drug and this 4-week Follow- up Visit.  
The following procedures and assessments for the 4- Week Follow-up Visit will be 
conducted: 
  
  
 
  
  
  
 
  
  
  
  
  
  
10.5 Early Discontinuation Visit  
Subjects may discontinue study treatment at any time for any reason (see Section  10.7).  
For subjects who discontinue study drug prior to having completed 24 weeks of treatment, 
every effort should be made to ensure that they return for Early Discontinuation procedures within 48 hours after discontinuing study drug. The procedures and assessments for Early 
Discontinuation will include all assessments in Section 10.3 and in the Schedule of 
Assessments in Section 20.1. 
After the Early Discontinuation Visit, these subjects will be required to return to the clinic  
4 weeks after completion of the Early Discontinuation Visit for a Follow -up Visit 
(Section 10.4). 
10.[ADDRESS_81849] subjects stay on schedule for study visits (Table 20-1).  

Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-[ADDRESS_81850] also be discontinued in the following instances: 
‚Ä¢ Unacceptable toxicity, as defined in the toxicity management section of the protocol 
(see Section  11.4.6), or which, in the judgment of the investigator, compromises the 
ability to continue study-specific procedures, or is considered to not be in the 
subject‚Äôs best interest  
‚Ä¢ Acute viral hepatitis  Types A, B, C, D, and E; autoimmune or alcoholic hepatitis; 
hypoxic/ischemic hepatopathy  
‚Ä¢ Subject request s to discontinue treatment for any reason  
‚Ä¢ Pregnancy during the course of the study 
‚Ä¢ Discontinuation of the study at the request of Tobira, Regulatory Agency  or 
Institutional Review Board (IRB) / Research Ethics Board (REB)  
If subjects discontinue from the study for reasons other than safety, replacement subjects will be considered. 
 

7RELUD7KHUDSHXWLFV,QF &HQLFULYLURF
&OLQLFDO6WXG\3URWRFRO  3DJHRI$PHQGPHQW
&21),'(17,$/  -XQH
678'<$66(660(176
 'HPRJUDSKLFDQG2WKHU3UHWUHDWPHQW$VVHVVPHQWV
$IWHUZULWWHQLQIRUPHGFRQVHQWLV REWDLQHGGHPRJUDSKLFGDWDDQ GDFRPSOHWHPHGLFDODQG
PHGLFDWLRQKLVWRU\ZLOOEHFROOHFW HGDWWKH6FUHHQLQJ9LVLW$ FRPSOHWHSK\VLFDOH[DPLQDWLRQ
LQFOXGLQJPHDVXUHPHQWVRIKHLJKWDQGERG\ZHLJKWZLOOEHSHUIRU PHG0HGLFDOKLVWRU\ZLOO
EHXSGDWHGXQWLOWKHILUVWGRVHRIV WXG\PHGLFDWLRQ$OO$(VZL OOEHUHFRUGHGIURPWKHWLPHRI
LQIRUPHGFRQVHQWDQGWKURXJKRXWW KHVWXG\UHJDUGOHVVRIDSSDUH QWFDXVDOLW\IURPXVHRIWKH
VWXG\WUHDWPHQW0HGLFDWLRQVWDN HQEHIRUHWKHI LUVWGRVHRIVWX G\GUXJZLOOEHUHFRUGHGDV
SULRUPHGLFDWLRQV
$VVHVVPHQWVRI(IILFDF\
7KLVVWXG\ZLOOHYDOXDWHWKHHIIHFWVRI&9&LQDGXOWVXEMHFWVZ LWK36& 





 $VVHVVPHQWVRI3KDUPDFRNLQHWLFV




 

 



$VVHVVPHQWVRI6DIHW\
$(VZLOOEHDVVHVVH GDWHDFKYLVLW
 $GYHUVH(YHQWVDQG6 HULRXV$GYHUVH(YHQWV
 'HILQLWLRQV
$GYHUVH(YHQW
$Q$(LVDQ\XQWRZDUGPHGLFDOR FFXUUHQFHLQDVXEMHFWRUFOLQLF DOLQYHVWLJDWLRQVXEMHFW
DGPLQLVWHUHGDSKDUPDFHXWLFDOSU RGXFWDQGZKLFKGRHVQRWQHFHVV DULO\KDYHDFDXVDO
UHODWLRQVKLSZLWKWKL VWUHDWPHQW$Q$(FD QWKHUHIRUHEHDQ\XQ IDYRUDEOHDQGXQLQWHQGHGVLJQ
Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 42 of 82 
Amendment 3  
 
 
CONFIDENTIAL    14 June2016  (including an abnormal laboratory finding), symptom, or disease temporally ass ociated with 
the use of a medicinal (investigational) product, whether or not related to the medicinal 
(investigational) product. 
[IP_ADDRESS].2 Adverse Drug Reaction 
An adverse drug  reaction (A DR) is defined as any AE caused by [CONTACT_2224] a pharmaceutical 
product. Adver se reactions are a subset of all suspected adverse reactions for which there is 
reason to conclude that the pharmaceutical product caused the event.  
[IP_ADDRESS].3 Suspected Adverse Reaction  
Suspected adverse reaction  means any AE for which there is a reasonable possibi lity that the 
study treatment caused the AE. ‚ÄúReasonable possibility‚Äù means there is evidence to suggest a 
causal relationship between the study treatment and AE. A suspected adverse reaction 
implies a lesser degree of certainty about causality than adverse reaction, which means an AE 
caused by a study treatment.  
[IP_ADDRESS].4 Unexpected Adverse Event or Reaction 
An AE or suspected adverse drug reaction is considered ‚Äúunexpected‚Äù if it is not listed in the 
investigator brochure or is not listed at the specificity or severity that has been observed; or, 
if an investigator brochure is not required or available, is not consistent with the risk information described in the general investigational plan.  
[IP_ADDRESS].5 Events Related to Disease Under Study   
Worsening of a pre- existing illnes s other than the disease under study will be assessed as an 
AE. If such an AE meets the definition of an SAE (see Section  [IP_ADDRESS].9), it must be 
reported as such (see Section  [IP_ADDRESS]).  
[IP_ADDRESS].[ADDRESS_81851] be 
reported as an AE. A clinically significant abnormality is a confirmed abnormality (by [CONTACT_75481]) that is changed sufficiently from Baseline so that in the judgment of the investigator a 
change in management is warranted. This  alteration may include: monitoring the laboratory 
test further, initiating other diagnostic tests or procedures, changing ongoing treatment, or administering new treatment. See Section  [IP_ADDRESS] for details regarding the management and 
monitoring of laboratory abnormalities of interest . 
[IP_ADDRESS].7 Surgical Procedures  
Surgical procedures themselves are not AEs; they are therapeutic measures for conditions that require surgery. The condition for which the surgery is required may be an AE, if it 
occurs or is detected during the study period. Planned surgical measures permitted by [CONTACT_49894](s) leading to these measures are not AEs, if the condition(s) was (were) known before the start of the study treatment. In the latter case, the condition should be reported as medical history. 
Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 43 of 82 
Amendment 3  
 
 
CONFIDENTIAL    14 June2016  [IP_ADDRESS].8 Overdose 
Tobira also considers the occurrence of overdose (regardless of adverse outcome) as an event 
that must be reported as an AE. An overdose is defined as a subject‚Äôs report of taking more 
than 1 tablet of study medication (i.e., more than 1 tablet per day of CVC). Overdose of any concomitant medication without any signs and symptoms will not be considered an AE. For reporting purposes, overdose will be considered an SAE only if any of the seriousness criteria are met (see definition in Section  [IP_ADDRESS].9).  
[IP_ADDRESS].9 Serious Adverse Event or Serious Adverse Reaction  
An AE or suspected adverse reaction is considered serious if, in the view of either the investigator or Sponsor, it results in any of the following outcomes: 
‚Ä¢ Death 
‚Ä¢ Life-threatening AE  
‚Ä¢ An AE or suspected AE is considered life- threatening if, in the view of either the 
investigator or Sponsor, its occurrence places the patient or subject at immediate risk 
of death. It does not include an AE or suspected adverse reaction that, had it occurr ed 
in a more severe form, might have caused death.  
‚Ä¢ Inpatient hospi[INVESTIGATOR_059]  (i.e., admission, overnight stay) or prolongation of existing 
hospi[INVESTIGATOR_059]  
‚Ä¢ Persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions 
‚Ä¢ Congenital anomaly/birth defect 
‚Ä¢ Important medical events  
‚Ä¢ An important medical event is one that, when based upon appropriate medical judgment, may jeopardize the subject and may require medical or surgical 
intervention to prevent one of the outcomes listed above in the definition of an SAE. (Examples of such events include allergic bronchospasm requiring intensive treatment at an emergency room or at home, blood dyscrasias, convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse.) 
[IP_ADDRESS] Adverse Event Recording  
AEs fall into the categories of ‚Äúnonserious‚Äù and ‚Äúserious.‚Äù From the time of informed consent and throughout the study, all AEs must be recorded in the CRF , regardless of 
apparent causality f rom use of the study treatment. The AE should be reported in standard 
medical terminology. If known, the diagnosis of the underlying illness or disorder should be recorded, rather than its individual symptoms. If a definitive diagnosis is not possible, the individual symptoms and signs should be recorded. 
The following information should be captured for all AEs: date of onset and end date or 
outcome (e.g., ongoing), severity of the event, seriousness of the event, investigator‚Äôs opi[INVESTIGATOR_12658] (CVC), action taken with regard to any of the 
Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 44 of 82 
Amendment 3  
 
 
CONFIDENTIAL    14 June2016  study medication and treatment required for the AE, cause of the event (if known), and 
information regarding the resolution/outcome. 
AEs classified as serious must be recorded on the appropriate SAE reporting tool and 
reported to Tobira using expeditious handling to comply with regulatory requirements (see 
Section [IP_ADDRESS]).  
[IP_ADDRESS] Adverse Event Classification  
 
 
 
 
 
  
 
  
 
  
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  

Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 45 of 82 
Amendment 3  
 
 
CONFIDENTIAL    14 June2016   
 
 
 
 
 
 
 
  
  
[IP_ADDRESS] Adve
rse Event Coding 
AE verbatim terms provided by [CONTACT_75482] (MedDRA), Version 16.0 or later. 
[IP_ADDRESS] Reporting of Serious Adverse Events 
Tobira is required to expedite to regulatory authorities reports of SAEs, s erious ADRs,  or 
S[LOCATION_003]Rs in line with relevant legislation or regulations , including the applicable US FDA 
Code of Federal Regulations, the European Commission Clinical Trials Directive 
(2001/20/EC), and other country specific legislation or regulations. Expectedness of SAEs will be determined by [CONTACT_75483].  
Any SAE , serious ADR  or S[LOCATION_003]R that occurs during the study from the time of signing the 
ICF to within [ADDRESS_81852] below:  
SAE Contact   
[CONTACT_75484]:   
 
 
 
 
 
 
  
   
   
  
 
  
  

Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-[ADDRESS_81853]:   
  
 
 
 
    
  
 
     
 
 
  
  
 
T
he required SAE information must be completed on the SAE F orm (MedWatch or CIOMS) . 
Tobira may request additional information from the investigator to ensure the timely  
completion of accurate safety reports.  
A copy of the submitted SAE form must be retained on file by [CONTACT_093]. The 
investigator must submit the SAE to the IRB/IEC according to local requirements and retain 
documentation of these submissions in the site study file.  
The investigator must take all therapeutic measures necessary for resolution of the SAE. Any medications necessary for treatment of the SAE must be recorded onto the concomitant medication section of the subjec t‚Äôs CRF and the event description section of the SAE Form. 
If the investigator detects an SAE in a study subject after the end of the period of 
observation, and considers the event possibly related to prior study treatment, he/she should contact [CONTACT_75485]. 
In case of emergency, contact [CONTACT_75486] (see Section  [IP_ADDRESS] for contact 
[CONTACT_3031]). The Investigator  will receive a safety letter notifying them of r elevant S[LOCATION_003]R reports. The 
investigator should notify the IRB/IEC as soon as is practical, of serious events in writing 
where this is required by [CONTACT_31665], and in accordance with the local institutional policy.  
In accordance with the European Union Clinical Trials Directive (2001/20/EC), Tobira or 
specified designee will notify worldwide regulatory authorities and the relevant Ethics 
Committe es in concerned Member States o f applicable S[LOCATION_003]Rs as individual notifications 
or through a periodic line listing.  
[IP_ADDRESS] Follow-up of AEs and SAEs 
AEs (including SAEs) will be collected from the time  of informed consent, throughout the 
treatment period, until [ADDRESS_81854]‚Äôs report should be supplied if and when available.  
[IP_ADDRESS] Pregnancy  
If a subject becomes pregnant during the study, the subject must be instructed to discontinue 
study drug and inform the investigator immediately. The investigator should report all 
pregnancies occurring in a subject or partner of a subject participating in the stu dy that occur 
up to [ADDRESS_81855] regarding the possible effects of prior study drug exposure on the fetus and the need to inform the study site of the outcome of the pregnancy. 
Any pregnancy complication or elective termination of a pregnancy for medical reasons will 
be recorded as an AE or a SAE. Elective abortion procedures, without complications, should not be considered as AEs. 
All reports of congenital abnormalities/birth defects and spontaneous abortions/miscarriages 
should be reported as an SAE for this study. Furthermore, any SAE occurring as an adverse pregnancy outcome post study must be reported to Tobira Drug Safety . 
All pregnancies that occur during the study should be reported using the Pregnancy Report Form, which should be faxed to Tobira Drug Safety within [ADDRESS_81856] has discontinued study drug do not require monitoring.  
11.4.2 Laboratory Assessments 
[IP_ADDRESS] Measurement of Laboratory Assessments  
A central laboratory will perform all  clinical safety laborato ry tests. Urine drug screens will 
also be analyzed at the central  laboratory. Urine pregnancy tests will be performed at the site 
using a dipstick method, except at Screening where a serum pregnancy test will be performed . If there is a positive urine preg nancy test  while on-study , a serum pregnancy test 
will be conducted by [CONTACT_6626].  
Samples for hematology, serum chemistry, liver function tests and urinalysis will be prepared 
using standard procedures. Refer to the laboratory manual provided by [CONTACT_75487], processing, and shipment.  
Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-[ADDRESS_81857] of all laboratory tests is provided in Appendix 20.5. 
[IP_ADDRESS] Clinically Significant Laboratory Abnormalities  
Any laboratory test showing abnormal results (including those recorded as AEs) that are 
believed to be possibly/probably relat ed to study drug treatment will be repeated weekly (or 
as often as deemed prudent by [CONTACT_093]) until the abnormality is resolved, returns to Baseline, or is otherwise explained. Whenever possible, the etiology of the abnormal findings will be documented on the CRF . See Section  [IP_ADDRESS].6 for a definition of clinically 
significant laboratory abnormality.  For management of subjects with elevated  liver tests, 
please refer to Section  [IP_ADDRESS].  
11.4.3 Vital Signs  
Vital sign measurements (systolic and diastolic blood pressure, temperature, heart rate, and respi[INVESTIGATOR_1487]) will be taken at each  visit. For subjects who discontinue study medication 
early, vital signs will be measured at the Early Discontinuation Visit within [ADDRESS_81858]. 
11.4.4 Electrocardiogram  
A 12-lead ECG w ill be taken at the Baseline/Day [ADDRESS_81859]. 
11.4.5 Physical Examination 
A complete physical examination will be performed at the Screening 1 Visit and the 
Baseline/Day 1 Visit. A symptom- directed physical examination will be performed, as 
needed, at the Screening 2 Visit, at all On-treatment Visits,  at the Early Discontinuation Visit 
within 48 hours of stoppi[INVESTIGATOR_14930], and at the 4- Week Follow-up Visit. The 
complete physical examination will include (but not limited to) the following organ or body system assessments: skin; head, eyes, ears, nose, and throat; thyroid; lungs; cardiovascular; abdomen (liver and spleen); extremities; lymph nodes; and a brief neurological exam. Abbreviated symptom- directed physical examinations will target signs and symptoms ; any 
abnormal findings that are reported as AEs will be recorded in the CRF . 
11.4.6 Toxicity Management 
Clinical events and clinically significant laboratory abnormalities will be graded according NCI CTCAE version 4.03 (Appendix 20.2).  
  
 

Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 49 of 82 
Amendment 3  
 
 
CONFIDENTIAL    14 June2016    
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 

Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 50 of 82 
Amendment 3  
 
 
CONFIDENTIAL    14 June2016  [IP_ADDRESS] Management of Subjects w ith Elevated ALP, ALT, AST or Bilirubin 
If a subject is asymptomatic  but experiences clinically significant elevations of liver 
transaminases or B ilirubin, subjects must repeat physical examination and laboratory 
evaluation within 48-[ADDRESS_81860] interrupt study drug. Close 
monitoring of study subjects includes: 
  
 
    
  
  
 
 
  
  
  
  
 
 
 
 
   
 
  
 
  
 
 
   
  

Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-[ADDRESS_81861] at  Baseline and at Weeks 12 and 24. 
11.6 Assessments of Medication Adherence 
Drug accountability through the assessment of pi[INVESTIGATOR_75466]-treatment evaluation visit.   
 
 
 
 
 
 
 
 
 
 
 

7RELUD7KHUDSHXWLFV,QF &HQLFULYLURF
&OLQLFDO6WXG\3URWRFRO  3DJHRI$PHQGPHQW
&21),'(17,$/  -XQH
67$7,67,&6
 6DPSOH6L]HDQG3RZHU
7KLVLVDVLQJOHDUPRSHQODE HO3R&VWXG\LQDGXOWVXEMHFW VZLWK36&DQGIRUZKLFKHDFK
SDWLHQWZLOOVHUYHDVWKHLURZQF RQWUROZKHQREVHUYLQJ$/3UHOD WLYHWR%DVHOLQH:LWKUHVSHFW
WRDSRWHQWLDOUDQJHRIIRU ZRUVHQLQJWRIRULPSURYHPH QWLQSHUFHQW$/3FKDQJH
IURP%DVHOLQHWRZHHNVDUHDVRQ DEO\DSSOLFDEOHVWDQGDUGGHY LDWLRQLV7KXV
SRZHUZRXOGDSSO\IRUWKHWZRVL GHGFRQILGHQFHLQWHUYDOIRU PHDQSHUFHQWFKDQJHIURP
%DVHOLQHWRZHHNVWRKDYHLWVORZHUOLPLWH[FHHGLIWKH WUXHPHDQSHUFHQWFKDQJH
IURP%DVHOLQHWRZHHNVLVDWOHDVW$OVRIRUDGLFKRWRP RXVUHVSRQGHUFULWHULRQVXFK
DVHLWKHUD$/3GHFUHDVHIURP %DVHOLQHWRZHHNVRUDQ$/ 3GHFUHDVHWR[8/1DW
ZHHNVSRZHUZRXOGDSSO\IRUWKHWZRVLGHGFRQILGHQ FHLQWHUYDOWRKDYHLWV
ORZHUOLPLWH[FHHGLIWKHWUXH UHVSRQGHUSHUFHQWDJHLVDWO HDVW7KXVLQWKLVVHQVHD
VDPSOHVL]HRILVVXIILFLHQWW RGHWHUPLQHLIWKHUHLVDSRVL WLYHVLJQDOLQ$/3GXULQJ&9&
WUHDWPHQW
*HQHUDO&RQVLGHUDWLRQV
'HVFULSWLYHVWDWLVWLFDOPHWKRGV ZLOOEHXVHGWRV X[COMPANY_003]UL]HWKHG DWDIURPWKLVVWXG\8QOHVV
VWDWHGRWKHUZLVHWKHWHUP¬≥GHV FULSWLYHVWDWLVWLFV¬¥UHIHUVWRQ XPEHURIVXEMHFWVQPHDQ
PHGLDQVWDQGDUGGHY LDWLRQ6'PLQLPXPDQGPD[LPXPZLWKTXD UWLOHVWKSHUFHQWLOH
DQGWKSHUFHQWLOHZKHQXVHIXO IRUFRQWLQXRXVGDWDDQGIUHTX HQFLHVDQGSHUFHQWDJHVIRU
FDWHJRULFDOGDWD
 $QDO\VLV3RSXODWLRQV
,QWHQWLRQWR7UHDW,773RSXODWLRQ 7KH,77SRSXODWLRQZLOOLQFOXGHDOOVXEMHFWVHQUROOHG
WRUHFHLYHWUHDWPHQW
3HU3URWRFRO333RSXODWLRQ 7KH33SRSXODWLRQZLOOLQFOXGHD OOVXEMHFWVZKRDUHHQUROOHG 
KDYHQRFRQWUDLQGLFDWHGFRQFRPLWDQW PHGLFDWLRQVKDYHDGHTXDWH VWXG\PHGLFDWLRQ
FRPSOLDQFH
6DIHW\3RSXODWLRQ 7KHVDIHW\SRSXODWLRQZLOOLQFO XGHDOOVXEMHFWVZKRUHFHLYHG DWOHDVWRQH
GRVHRIVWXG\GUXJ7KLVSRSXOD WLRQZLOOEHXVHGI RUDOOVDIHW\ DQDO\VHV
 +DQGOLQJRI0LVVLQJ'DWD
'DWDZLOOEHDQDO\]HGDVUHFRUG HG7KHUHZLOOEHQRLPSXWDWLRQ VFRQGXFWHGIRU PLVVLQJGDWD
$VX[COMPANY_003]U\RIPLVVLQJGDWDZLOOEH LQFOXGHGLQWKHILQDOVWDWLVW LFDOUHSRUW
 6XEMHFW5HSODFHPHQW
,IDVXEMHFWGLVFRQWLQXHVIURPWKHVWXG\IRUUHDVRQVRWKHUWKDQ VDIHW\DUHSODFHPHQWVXEMHFW
ZLOOEHFRQVLGHUHGDQGLQFO XGHGLQWKHVWXG\DQDO\VLV 
 6XEMHFW'LVSRVLWLRQ
6XEMHFWGLVSRVLWLRQZLOOEHSUHVHQ WHGIRUDOOVXEMHFWV7KHQXP EHURIVXEMHFWVZKRFRPSOHWHG
WKHVWXG\DQGGLVFRQWLQXHGIURP WKHVWXG\ZLOOEHSURYLGHG7KH UHDVRQVIRUHDUO\
GLVFRQWLQXDWLRQDOVRZLOOEHSUHVHQWHG
Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 53 of 82 
Amendment 3  
 
 
CONFIDENTIAL    14 June2016  12.4 Efficacy 
12.4.1 Efficacy Endpoint 
The primary e fficacy endpoint for this study is the percent c hange from Baseline through 
Week 24 in serum alkaline phosphatase.  
 
 
12.4.2 Methods of Analysis for Primary and Secondary Efficacy Endpoints 
Percent changes in  ALP from Baseline will be summarized using descriptive statistics for the 
respective pre- treatment and on -treatment visits .   
 
 
 
 
 
  
 
 
 
 
12.5 Safety 
12.5.1 Safety Endpoints  
Safety endpoints include: 
‚Ä¢ Evaluation of the safety and tolerability through 24 weeks of treatment in adult PSC 
subjects 
‚Ä¢ Evaluation of AE s, clinical laboratory tests, physical exam and 12 -lead ECG.  
 

Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 54 of 82 
Amendment 3  
 
 
CONFIDENTIAL    14 June2016  12.5.2 Methods of Analysis for Safety Endpoints 
[IP_ADDRESS] Adverse Events  
AEs will be tabulated by [CONTACT_75488] -organ classification. The 
occurrence of TEAEs will be summarized by [CONTACT_75489], system organ classifications, and severity (see Sections  [IP_ADDRESS] and  [IP_ADDRESS]).   
All AEs will be listed for individual subjects showing both verbatim and preferred terms. 
Separate summaries of treatment -emergent SAEs and TEAE s related to study drug will be 
generated.  
Any event reported on the CRF  that occurs on or after the initiation of study drug is defined 
as treatment -emergent. Additionally, it is assumed that an AE that was rep orted to have 
started on Day [ADDRESS_81862] occurred after the initiation of study drug. Hence, AEs occurring on Day 1 with no associated onset time are assumed to be treatment -emergent.  
[IP_ADDRESS] Clinical Laboratory Tests   
Descriptive s ummaries of clinical laboratory results will be presented by [CONTACT_15449]. 
Laboratory abnormalities will be graded according to NCI CTCAE version 4.03 (see Appendix 20.2). The number and percentage of subjects experiencing treatment- emergent 
graded toxicities will be summarized by [CONTACT_75490]. Laboratory toxicity shifts from Baseline to post- Baseline assessments will be summarized by [CONTACT_6490]. Changes from Baseline in laboratory tests will be summarized for each treatment 
group. 
[IP_ADDRESS] Physical Examination and Vital Signs  
Any abnormal findings that are considered clinically significant in the opi[INVESTIGATOR_75467], if already present at 
Screening . 
Descriptive summaries of vital signs will be presented by [CONTACT_15449]. Descriptive summaries of quantitative changes in vital signs will be presented by [CONTACT_67486]. Vital sign results will be reviewed for clinically notable abnormalities, according to predefined criteria, and adverse changes will be summarized.   
[IP_ADDRESS].1 Electrocardiograms  
ECG results will be reviewed locally for clinically notable abnormalities a ccording to 
predefined criteria. Patients exhibiting Grade 3 or 4 PR or QTc interval will be summarized.  
[IP_ADDRESS].2 Prior and Concomitant Medications 
Prior and concomitant medications will be mapped to a World Health Organization  preferred 
term and drug classificatio n. The number and percent of subjects taking concomitant 
medications will be summarized using preferred terms and drug classifications.  
Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 55 of 82 
Amendment 3  
 
 
CONFIDENTIAL    14 June2016    
 
 
  
  
   
  
 
   
  
 
   
  
  

7RELUD7KHUDSHXWLFV,QF &HQLFULYLURF
&OLQLFDO6WXG\3URWRFRO  3DJHRI$PHQGPHQW
&21),'(17,$/  -XQH
48$/,7<&[ZIP_CODE]/$1' 48$/,7<$6685$1&(
 6SRQVRU$XGLWV
'XULQJWKHVWXG\LQGLYLGXDOVIURPWKH7RELUD4XDOLW\$VVXUDQFH GHSDUWPHQWDQGRUWKHLU
DXWKRUL]HGUHSUHVHQWDWLYHPD\YL VLWWKHLQYHVWLJDWRU¬∂VVLWHWR FRQGXFWDQDXGLWRIWKHVWXG\
7KHSXUSRVHRIWKLVYLVLWZLOOEH WRGHWHUPLQHWKHLQYHVWLJDWRU ¬∂VDGKHUHQFHWRWKHSURWRFRO
DSSOLFDEOHUHJXODWLRQVDQG7REL UD¬∂VSURFHGXUHVLQDGGLWLRQWR DVVHVVLQJWKHDFFXUDF\RIWKH
VWXG\GDWD3ULRUWRLQLWLDWLQJWKLVDXGLWWKHLQYHVWLJDWRUZL OOEHFRQWDFWHGE\7RELUDWR
DUUDQJHDFRQYHQLHQWWLPHIRUWKL VYLVLW7KHLQYHVWLJDWRUDQG VWDIIDUHH[SHFWHGWRFRRSHUDWH
ZLWKWKHDXGLWRUVDQGDOORZDFFH VVWRDOOVXEMHFWUHFRUGVVXSSR UWLQJWKH&5)VDQGRWKHU
VWXG\UHODWHGGRFXPHQWV
,QVSHFWLRQE\5HJXO DWRU\$XWKRULWLHV
$WVRPHSRLQWGXULQJWKHLQYHVWLJ DWLRQDOSURGXFW¬∂VGHYHORSPHQW SURJUDPDUHJXODWRU\
DXWKRULW\PD\YLVLWWKHLQYHV WLJDWRUWRFRQGXFWDQLQVSHFWLRQR IWKHVWXG\DQGWKHVLWH7KH
LQYHVWLJDWRUDQGVWDIIDUHH[S HFWHGWRFRRSHUDWHZLWKWKHLQVSH FWRUVDQGDOORZDFFHVVWRDOO
VRXUFHGRFXPHQWVVXSSRUWLQJWKH &5)VDQGRWKHUVWXG\UHODWHGGR FXPHQWV7KHLQYHVWLJDWRU
PXVWLPPHGLDWHO\QRWLI\7RELUDZ KHQFRQWDFWHGE\DQ\UHJXODWRU\ DXWKRULW\IRUSXUSRVHVRI
FRQGXFWLQJDQLQVSHFWLRQ
7RELUD7KHUDSHXWLFV,QF &HQLFULYLURF
&OLQLFDO6WXG\3URWRFRO  3DJHRI$PHQGPHQW
&21),'(17,$/  -XQH
(7+,&6$1'3527(&7,212)+80$168%-(&76
 &RPSOLDQFH6WDWHPHQW
7KHLQYHVWLJDWRUDJUHHVWRFRQGXFWWKHVWXG\LQFRPSOLDQFHZLWK WKHSURWRFRO,&+(*RRG
&OLQLFDO3UDFWLFH* &3JXLGHOLQHVDQGD OOORFDODQGQDWLRQDO UHJXODWLRQV
7KHLQYHVWLJDWRUPXVWDGKHUHW RWKHSURWRFRODVGHVFULEHGLQWK LVGRFXPHQWDQGDJUHHWKDW
GHYLDWLRQVWRWKHSURW RFROZLWKWKHH[FHSWLRQRIPHGLFDOHPHUJ HQFLHVPXVWEHGLVFXVVHGDQG
DSSURYHGE\7RELUDSULRUWRVHHNLQ JDSSURYDOIURPWKH,5%,(& 7KHLQYHVWLJDWRULV
UHVSRQVLEOHIRUHQUROOLQJVXEMHFW VZKRKDYHPHWWKHSURWRFROLQ FOXVLRQDQGH[FOXVLRQFULWHULD
RUPXVWKDYHREWDLQHGSU LRUGRFXPHQWHGDSSU RYDOIURP7RELUDSUL RUWRHQUROOPHQWLQWKH
VWXG\7KH,5%,(&WKDWJUDQWH GRULJLQDODSSURYDORUWKH,5%, (&FXUUHQWO\UHVSRQVLEOHIRU
RYHUVHHLQJWKHFRQGXFWRIWKHV WXG\PXVWEHQRWLILHGRIDOOFK DQJHVLQDQGGHYLDWLRQVIURP
WKHSURWRFROWKDWPD\LQFUHDVH ULVNWRWKHVXEMHFWDQGRUWKDW PD\DGYHUVHO\DIIHFWWKHULJKWV
RIWKHVXEMHFWRUYDOLGLW\RIWKH LQYHVWLJDWLRQ7KHLQYHVWLJDW RUPXVWVHQGDFRS\RIWKH
DSSURYDOOHWWHUIURPWKH,5%,( &WR7RELUDDQGUHWDLQWKHRULJL QDOLQWKHVLWHVWXG\UHJXODWRU\
ILOH
,QVWLWXWLRQDO5HYLHZ%RDUG,QGHSHQGHQW(WKLFV&RPPLWWHH
,WLVWKHUHVSRQVLELOLW\RIWKHLQYHVWLJDWRUWRDVVXUHWKDWDOO DVSHFWVRIWKHHWKLFVUHYLHZDUH
FRQGXFWHGLQDFFRUGDQFHZLWKWKH' HFODUDWLRQRI+HOVLQNL2FWRE HUDVGHVFULEHGLQWKH
,&+(*&3DQGRUORFDOODZV ZKLFKHYHUSURYLGHVWKHJUHDWHVW OHYHORISURWHFWLRQIRUWKH
VWXG\SDUWLFLSDQWV7KHSURWRF RODQGDQ\LQIRU PDWLRQVXSSOLHGW RWKHVXEMHFWWRREWDLQ
LQIRUPHGFRQVHQWLQFOXGLQJZULWWHQ,&)VVXEMHFWUHFUXLWPHQW SURFHGXUHV
HJDGYHUWLVHPHQWVDQGZ ULWWHQLQIRUPDWL RQWREHSURYLGHG WRVXEMHFWVLQIRUPDWLRQ
OHDIOHWVPXVWEHUHYLHZHGDQGD SSURYHGE\DTXDOLILHG,5%,(& SULRUWRHQUROOPHQWRI
SDUWLFLSDQWVLQWKHVWXG\3ULR UWRLQLWLDWLRQRIWKHVWXG\7R ELUDPXVWUHFHLYHGRFXPHQWDWLRQ
RIWKH,5%,(&DSSURYD OZKLFKVSHFLILFDOO\LGHQWLILHVWKHVWXG \SURWRFRODQGDOLVWRIWKH
FRPPLWWHHPHPEHUV
$PHQGPHQWVWRWKHSURWRFRODQGU HYLVLRQVWRWKHLQIRUPHGFRQVHQ WPXVWDOVREHVXEPLWWHGWR
DQGLIUHTXLUHGDSSURYHGE\WKH,5%,(&
,QYHVWLJDWRUVPXVWVXEPLWSURJUH VVUHSRUWVWRWKH,5%,(&LQDF FRUGDQFHZLWKWKH,5%,(&
UHTXLUHPHQWV$QQXDOUHDSSURYDO RIWKHVWXG\PXVWEHREWDLQHG &RSLHVRISURJUHVVUHSRUWV
DQGDQQXDOUHDSSURYDOVP XVWEHVHQWWR7RELUD
:KHQ7RELUDSURYLGHVWKHLQYHVWLJ DWRUZLWKDVDIHW\UHSRUWWKH LQYHVWLJDWRUPXVWSURPSWO\
IRUZDUGDFRS\WRWKH,5%,(&
$IWHUFRPSOHWLRQRUWHUPLQDWLRQRI WKHVWXG\WKHLQYHVWLJDWRU PXVWVXEPLWDILQDOUHSRUWWR
WKH,5%,(&DQGWR7RELUD
7KHLQYHVWLJDWRUDVSDUWRIWKH UHFRUGVUHWHQWLRQUHTXLUHPHQWV IRUWKHVWXG\PXVWPDLQWDLQ
GRFXPHQWDWLRQRIDOOVXEPLVVLRQV FRUUHVSRQGHQFHDQGDSSURYDOV WRDQGIURPWKH,5%,(&
7KHLQYHVWLJDWRULVUHVSRQVLEO HIRUFRQGXFWLQJWKHVWXG\LQDFF RUGDQFHZLWKWKHSURWRFRODOO
DSSOLFDEOHODZVUHJXODWLRQVDQG*&3DFFRUGLQJWR,&+JXLGHOLQ HV
Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-[ADDRESS_81863] the IRB/IEC‚Äôs written approval/favorable opi[INVESTIGATOR_75468]. 
Before being enrolled in the clinical study, subjects must consent to participate after the 
nature, scope, and possible consequences of the study have been explained in a form understandable to them.  
An informed consent document that includes both information about the study and the 
consent form will be prepared and given to the subject. This document will contain all the 
elements required by [CONTACT_11580] E6 Guideline for Good Clinical Practice and an y additional 
elements required by [CONTACT_427]. The document must be in a language understandable to the subject and must specify who informed the subject. Where required by [CONTACT_1769], the person who informs the subject must be a physician. 
A copy of the signed consent document must be given to the subject. The original signed 
consent document will be retained by [CONTACT_093]. 
The investigator will not undertake any measures specifically required only for the clinical 
study until valid consent has been obtained. 
The investigator must inform the subject‚Äôs primary physician about the subject‚Äôs 
participation in the trial if the subject has a primary physician and if the subject agrees to the primary physician being informed. 
14.[ADDRESS_81864] be adhered to. The investigator and Tobira 
are responsible for ensuring that sensitive information is handled in accordance with local 
requirements (e.g., Health Insurance Portability and Accountability Act ). Appropriate 
consent and authorizations for use and disclosure and/or transfer (if applicable) of protected information must be obtained. 
Subject names will not be supplied to Tobira. Only the subject number and subject initials 
will be recorded in the CRF, and if the subject name [CONTACT_75502] (e.g., 
laboratory report), it must be obliterated on the copy of the document to be supplied to Tobira. Study findings stored on a computer will be stored in accordance with local data protection laws. The subjects will be informed that representatives of Tobira, IRB/IEC, or regulatory authorities may inspect their medical records to verify the information collected, and that all personal information made available for inspection will be handled in stri ctest 
confidence and in accordance with local data protection laws. 
Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-[ADDRESS_81865]  
The study will be conducted in compliance with the Declaration of Helsinki (October 2008) 
and the ICH E6 Guideline for GCP. All national, state, and local laws of the pertinent regulatory authorities will be followed.  
If it is necessary to amend either the protocol or the ICF, the investigator will be responsible for ensuring that the IRB/IEC reviews and approves the amended documents. Amended ICFs must be obtained and used for obtaining consent from new subjects. 
14.[ADDRESS_81866]. The investigator is to notify the IRB/IEC in writing of the study‚Äôs completion or early termination, and send a copy of the notification to Tobira and retain one copy for the site study regulatory file. 
  
7RELUD7KHUDSHXWLFV,QF &HQLFULYLURF
&OLQLFDO6WXG\3URWRFRO  3DJHRI$PHQGPHQW
&21),'(17,$/  -XQH
'$7$+$1'/,1*$1'5(&25'.((3,1*
 'DWD0DQDJHPHQW 5HVSRQVLELOLWLHV
$OO&5)GDWDZLOOEHHQW HUHGLQWRDYDOLGD WHGGDWDEDVH/DERUDW RU\GDWDZLOOEHUHFHLYHGDV
GDWDVHWVIURPWKHFHQWUDOODERUDWRU\RUGDWDUHFHLYHGLQDIRU PDWWKDWFDQEHFRQYHUWHG
WR 7KHODERUDWRU\GDWDZLOO EHUHFRQFLOHGDJDLQVWWKHEORRG DQGXULQHFROOHFWLRQH&5)V
LQWKHGDWDEDVH7KHODERUDWRU\ GDWD GDWDVHWVD ORQJZLWKWKH  GDWDVHWVFUHDWHGIURP
WKH('&GDWDZLOOEHSU RYLGHGWRWKHVWDWLVWLF LDQVDVQHHGHG
$OOGDWDHQWU\YHULILFDWLRQD QGYDOLGDWLRQZLOOEHSHUIRUPHG LQDFFRUGDQFHZLWKWKHFXUUHQW
VWDQGDUGRSHUDWLQJSURFHGXUHVRI 7RELUDRULWVGHVLJQHH7KHGD WDEDVHZLOOEHD XWKRUL]HGIRU
ORFNRQFHQRGDWDTXHULHVDUHRXWVW DQGLQJDOOVWXG\GDWDDUHF RQVLGHUHGFOHDQDQGDOOGHILQHG
SURFHGXUHVFRPSOHWHG
'DWD+DQGOLQJDQG5HFRUG.HHSLQJ
 'DWD&ROOHFWLRQDQG5HWULHYDO
7KHLQYHVWLJDWLYHVLWHZLOOEH SURYLGHGZLWKSDSHU&5)VLQZKLF KWRUHFRUGDOOWKHSURWRFRO
VSHFLILHGGDWDIRUHDFKVXEMHFWL QWKLVVWXG\(QWULHVPDGHLQ WKH&5)PXVWEHYHULILDEOH
DJDLQVWVRXUFHGRFXPHQWVRULQ FHUWDLQFLUFXPVWDQFHVDVGLUHFW HGE\7RELUDHQWULHVZLOOKDYH
EHHQGLUHFWO\HQWHUHGLQWRWKH &5)LQVXFKFDVHVWKHHQWU\LQ WKH&5)ZLOOEH FRQVLGHUHGDV
WKHVRXUFHGDWD'DWDUHSRUWHGL QWKH&5)WKDWDUHGHULYHGIURP VRXUFHGRFXPHQWVVKRXOGEH
FRQVLVWHQWZLWKWKHVRXUFHGRFXP HQWVRUWKHGLVFUHSDQFLHVVKRXO GEHH[SODLQHG
7KHLQYHVWLJDWRUZLOOEHUHVSRQVLE OHIRUUHYLHZL QJDOOGDWDDQG &5)HQWULHVDQGZLOOVLJQDQG
GDWHWKHGHVLJQDWHGSDJHVLQ HDFKVXEMHFW¬∂V&5)YHULI\LQJWKDW WKHLQIRUPDWL RQLVWUXHDQG
FRUUHFW
4XHULHVJHQHUDWHGE\'DWD0DQDJHP HQWDW ZLOOEHVHQWWRWKHVW XG\VLWHIRU
UHVROXWLRQ7KHLQYHVWLJDWRULVUH VSRQVLEOHIRUWKHUHYLHZDQG DSSURYDORIDOOUHVSRQVHVWR
&5)TXHULHV
 5HFRUGV5HWHQWLRQ
7KHLQYHVWLJDWRUPXVWHQVXUHWKD WDOOUHFRUGVSHUWDLQLQJWRWKH FRQGXFWRIWKHFOLQLFDOVWXG\
,&)VGUXJDFFRXQWDELOLW\UHFRUGV VRXUFHGRFXPHQWVDQGRWKHU VWXG\GRFXPHQWDWLRQDUH
DGHTXDWHO\PDLQWDLQHGIRUDSH ULRGRI\HDUVDIWHUWKHODVWDS SURYDORIDPDUNHWLQJ
DSSOLFDWLRQLQDQ,&+UHJLRQD QGXQWLOWKHUHDUHQRSHQGLQJRU FRQWHPSODWHGPDUNHWLQJ
DSSOLFDWLRQVLQDQ,&+UHJLRQRUD WOHDVW\HDUVKDYHHODSVHG VLQFHWKHIRUPDO
GLVFRQWLQXDWLRQRIFOLQL FDOGHYHORSPHQWRIW KHLQYHVWLJDWLRQDO SURGXFW
7KHLQYHVWLJDWRUPXVWQRWGHVWUR \DQ\UHFRUGVDVVRFLDWHGZLWKW KHVWXG\ZLWKRXWUHFHLYLQJ
DSSURYDOIURP7RELUD7KHLQYHVWLJ DWRUPXVWQRWLI\7RELUDLQWK HHYHQWRIDFFLGHQWDOORVVRU
GHVWUXFWLRQRIDQ\VWXG\UHFRUGV ,IWKHLQYHVWLJDWRUOHDYHVWK HLQVWLWXWLRQZKHUHWKHVWXG\ZDV
FRQGXFWHG7RELUDPXVWEHFRQWDFWH GWRDUUDQJHDOWHUQDWLYHUHFR UGVWRUDJHRSWLRQV
:KHQHYHUSRVVLEOHDQRULJLQDOU HFRUGLQJRIDQREVHUYDWLRQPXVW EHUHWDLQHGDVWKHVRXUFH
GRFXPHQW+RZHYHUDSKRWRFRS\RIDUHFRUGLVDFFHSWDEOHSURYLG HGLWLVOHJLEOHDQGLVD
YHULILHGFRS\RIWKHRULJLQDOGRFXPHQW
Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 61 of 82 
Amendment 3  
 
 
CONFIDENTIAL    14 June2016  All CRF data entered by [CONTACT_779] (including audit trail), as well as computer hardware and 
software (for accessing the data), will be maintained or made available at the site in compliance with applicable record retention regulations. Tobira wil l retain the original paper 
CRF data and audit trail.  
15.2.3 Study Monitoring and Access to Source Documents  
Qualified representatives of Tobira or its designees (‚Äústudy monitors‚Äù) will monitor the study 
according to a predetermined monitoring plan. Monitoring visits provide Tobira with the opportunities to do the following: 
‚Ä¢ Evaluate the progress of the study 
‚Ä¢ Verify the accuracy and completeness of CRFs 
‚Ä¢ Assure that all protocol requirements, applicable laws and/or regulations, and 
investigator‚Äôs obligations are be ing fulfilled  
‚Ä¢ Resolve any inconsistencies in the study records 
The investigator must allow the study monitors to periodically review, at mutually 
convenient times during the study and after the study has been completed, all CRF s and 
office, hospi[INVESTIGATOR_307], and laboratory records supporting the participation of each subject in the study. The CRF s and other documentation supporting the study must be kept up- to-date by 
[CONTACT_75491]. These study materials must be available for review by [CONTACT_11200], and/or other qualified representatives of Tobira, at each monitoring visit.  
The study monitor will review the various records of the study ( CRFs, subject medical and 
laboratory records, and other pertinent data). T he study monitor will verify the CRF data 
against original source documentation for accuracy and completeness. The study monitor will identify data discrepancies and collaborate with the investigator and research staff to resolve the discrepancies in a tim ely manner. Protocol deviations will also be identified and recorded 
on a ‚ÄúProtocol Deviation Log.‚Äù The study monitor will follow an ‚ÄúIssue Escalation‚Äù plan in order to ensure that each issue identified during a monitoring visit is appropriately documented, reported, and resolved in a timely manner in accordance with the plan‚Äôs requirements.  
  
Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 62 of 82 
Amendment 3  
 
CONFIDENTIAL    14 June2016   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 

Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 63 of 82 
Amendment 3  
 
 
CONFIDENTIAL    14 June2016   
 
 
 
 
 
 
  

7RELUD7KHUDSHXWLFV,QF &HQLFULYLURF
&OLQLFDO6WXG\3URWRFRO  3DJHRI$PHQGPHQW
&21),'(17,$/  -XQH
5()(5(1&(6
 +LUVFKILHOG*0.DUOVHQ7+/ LQGRU.'HWDO3ULPDU\VFOHURV LQJFKRODQJLWLV/DQFHW

&KDSPDQ5)HYHU\-.DOORR$HWDO'LDJQRVLVDQGPDQDJHPHQW RISULPDU\VFOHURVLQJ
FKRODQJLWLV+HSDWRORJ\
(DWRQ-(7DOZDONDU-$/D]DULGLV .1HWDO3DWKRJHQHVLVRI3U LPDU\6FOHURVLQJ
&KRODQJLWLVDQG$GYDQFHVLQ'LDJ QRVLVDQG0DQDJHPHQW*DVWURHQW HURORJ\

)LRURWWR56FLUSR57UDXQHU0H WDO/RVVRI&)75DIIHFWVEL OLDU\HSLWKHOLXPLQQDWH
LPPXQLW\DQGFDXVHV7/51)»õ%P HGLDWHGLQIOD[COMPANY_003]WRU\UHVSRQVHL QPLFH
*DVWURHQWHURORJ\
6SLUOL&1DWKDQVRQ0+)LRURWWR5 HWDO3URLQIOD[COMPANY_003]WRU\F\WR NLQHVLQKLELWVHFUHWLRQLQ
UDWELOHGXFWHSLWKHOLXP*DV WURHQWHURORJ\ 
$URQ-+%RZOXV&/7KHLPPXQRELRORJ\RISULPDU\VFOHURVLQJFKR ODQJLWLV6HPLQ
,PPXQRSDWKRO
+DUDGD.1DNDQXPD<,QQDWHLPP XQLW\LQWKHSDWKRJHQHVLVRIFK RODQJLRSDWK\DUHFHQW
XSGDWH,QIOD[COMPANY_003]WLRQ	$OOHUJ\GU XJWDUJHWV
3ULHVWHU6:LVH&*ODVHU66, QYROYHPHQWRIFKRODQJLRF\WHSUR OLIHUDWLRQLQELOLDU\
ILEURVLV:RUOG-*DVWURLQWHV W3DWKRSK\VLRO
/HH6-.LP.+3DUN..0HFKDQLVPV RIILEURJHQHVLVLQOLYHUFL U[LOCATION_006]RVLV7KHPROHFXODU
DVSHFWVRIHSLWKHOLDOPHVHQFK\ PDOWUDQVLWLRQ:RUOG-+HSDWRO 
2PHQHWWL$3RUUHOOR$-XQJ<HWDO+HGJHKRJVLJQDOLQJUHJXO DWHVHSLWKHOLDO
PHVHQFK\PDOWUDQVLWL RQGXULQJELOLDU\ILEUR VLVLQURGHQWVDQGK XPDQV-&OLQ,QYHVW

%DPEKD..LP:57DOZDONDU-HW DO,QFLGHQFHFOLQLFDOVSHFW UXPDQGRXWFRPHVRI
SULPDU\VFOHURVLQJFKRODQJLWLVLQD8QLWHG6WDWHVFRPPXQLW\*D VWURHQWHURORJ\

%RRQVWUD.:HHUVPD5.YDQ(USHF XP.-HWDO(SL36&3%&6WXG\ *URXS3RSXODWLRQ
EDVHGHSLGHPLRORJ\PDOLJQDQF \ULVNDQGRXWFRPHRISULPDU\VFO HURVLQJFKRODQJLWLV
+HSDWRORJ\
0RORGHFN\1$.DUHHPL+3DUDE5 ,QFLGHQFHRISULPDU\VFOHURVL QJFKRODQJLWLVD
V\VWHPDWLFUHYLHZDQGPHWDDQ DO\VLV+HSDWRORJ\ 
.DSODQ**/DXSODQG.%%XW]QHU 'HWDO7KHEXUGHQRIODUJHD QGVPDOOGXFWSULPDU\
VFOHURVLQJFKRODQJLWLVLQDGXOWV DQGFKLOGUHQD SRSXODWLRQEDV HGDQDO\VLV$P-
*DVWURHQWHURO
Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 65 of 82 
Amendment 3  
 
 
CONFIDENTIAL    14 June2016  15. Weisner RH, Grambsch PM, Dickson ER. Primary sclerosing cholangitis: natural history, 
prognostic factors and survival analysis. Hepatology 1989;10(4):430-6. 
16. Ali AH, Carey EJ, Lindor KD. Current research on the treatment of primary sclerosing cholangitis. Intractable Rare Dis Res. 2015;4(1):1-6. 
17. Broome U, Olsson R, L√∂√∂f L, et al. Natural history and prognostic factors in 305 Swedish 
patients with primary sclerosing cholangitis. Gut. 1996; 38:610-15. 
18. Tischendorf J, Hecker H, Kr√ºger M, et al. Characterization, Outcome, and Prognosis in 
273 Patients with Primary Sclerosing Cholangitis: A Single Center Study . Am J 
Gastroenterology 2007; 102:107-14. 
19. Lindor KD, Kowdley KV, Luketic VA. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. 2009;50(3):808-14. 
20. Beuers U, Spengler U, Kruis W, et al. Ur sodeoxycholic acid for treatment of primary 
sclerosing cholangitis: a placebo -controlled trial. Hepatology. 1992;16(3):707-14. 
21. Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis -Ursodeoxycholic Acid Study Group. NEJM. 1997;336(10):691-5. 
22. Mitchell SA, Bansi DS, Hunt N, Von Bergmann K, Fleming KA, Chapman RW. A preliminary trial of high -dose ursodeoxycholic acid in primary sclerosing cholangitis. 
Gastroenterology. 2001;121:900‚Äì907. 
23. Olsson R, Boberg KM, de Muckadell OS. High -dose ursodeoxycholic acid in primary 
sclerosing cholangitis: a 5 -year multicenter, randomized, controlled study. 
Gastroenterology. 2005;129(5):1464-72. 
24. Lindstrom L, Hultcrantz  R, Boberg KM, et al. Association Between Reduced Levels of 
Alkaline Phosphatase and Survival Times of Patients With Primary Sclerosing Cholangitis.  Clinical Gastro and Hepatol. 2013;11(7):841-46. 
25. Eaton JE, Silveira MG, Pardi DS, et al.  High-Dose Ursodeoxycholic Acid Is Associated 
With the Development of Colorectal Neoplasia in P atients With Ulcerative Colitis and 
Primary Sclerosing Cholangitis. Am J Gastroenterology. 2011;106:1638-45. 
26. Beuers U, Boberg K, Chapman R, et al. EASL Practice Guidelines. J Hepatology. 2009;51:237‚Äì67. 
27. Ponsioen CY, Chapman RW, Chazouill√®res O. Surrogate e ndpoints for clinical trials in 
primary sclerosing cholangitis; review and results from an International PSC Study Group consensus process. Hepatology. 2015 Sep 29. doi: 10.1002/hep.[ZIP_CODE][Epub ahead of print]. 
Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 66 of 82 
Amendment 3  
 
 
CONFIDENTIAL    14 June2016  28. Rupp C, Rossler A, Halibasic E. Reduction in alkaline phosphatase is associated with 
longer survival in primary sclerosing cholangitis, independent of dominant stenosis. Alimentary Pharmacology and Therapeutics, 2014;40(11-12):1291-301. 
29. Stanich PP, Einar Bj√∂rnsson, Andrea A. Gossard. Alkaline phospha tase normalization is 
associated with better prognosis in primary sclerosing cholangitis.  Digestive Liver 
Disease. 2011;43(4):309-13. 
30. Harada K, Nakanuma Y. Innate Immunity in the Pathogenesis of Cholangiopathy: A Recent Update. Inflammation & Allergy - Drug Targets;11(6):478-483. 
31. Marra F, Romanelli RG, Giannini C, et al. Monocyte chemotactic protein -1 as a 
chemoattractant for human hepatic stellate cells. Hepatology. 1999;29(1):140-8. 
32. Zimmermann HW, Tacke F. Modification of chemokine pathways and immune cel l 
infiltration as a novel therapeutic approach in liver inflammation and fibrosis. Inflamm Allergy Drug Targets. 2011;10(6):509-36. 
33. Mitchell C, Couton D, Couty JP, et al. Dual role of CCR2 in the constitution and the resolution of liver fibrosis in mice. Am J Pathol. 2009;174:1766-1775. 
34. Schwabe RF, Bataller R, Brenner DA. Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration. J Physiol Gastrointest Liver Physiol 2003;285:G949-G958. 
35. Saiman Y, Friedman S. The role of chemo kines in acute liver injury. Frontiers in 
Physiology. 2012;3:213. 
36. Seki E, De Minicis S, Gwak GY, et al. CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest. 2009;119:1858-70. 
37. Seki E, de Minicis S, Inokuchi S. CCR2 promotes hepatic fibrosis in mic e. Hepatology. 
2009;50(1):185-197. 
38. Miura K, Yang L, Rooijen NV, et al. Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2. Am J Physiol Gastrointest Liver Physiol. 2012;302:G1310-G1321. 
39. Tabibian JH, O'Hara SP, Splinter PL , et al. Cholangiocyte senescence by [CONTACT_34058] N -ras 
activation is a characteristic of primary sclerosing cholangitis. Hepatology. 2014; 59(6):2263-75. 
40. Tsuneyama K, Harada K, Yasoshima M, et al. Monocyte chemotactic protein-1, -2, and -
3 are distinctively exp ressed in portal tracts and granulomata in primary biliary cirrhosis: 
implications for pathogenesis. Journal of Pathology. 2001;193(1):102-09. 
Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-[ADDRESS_81867] A, Labori KJ, 
Raeder MG. Multiple inflammatory -, tissue remodelling - and fibrosis genes are 
differentially transcribed in the livers of Abcb4 (-/-) mice harbouring chronic cholangitis. Scand J Gastroenterol. 2007;42:1245‚Äì1255 
42. Henckaerts L, Pi[INVESTIGATOR_75469] M, Joossens M. Mutations in pattern recognition receptor g enes 
modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease. Gut. 2007;56(11):1536-42. 
43. Henckaerts L, Fevery J, Van Steenbergen W, et al. CC- type chemokine receptor [ADDRESS_81868] primary sclerosing ch olangitis. Inflamm Bowel Dis. 
2006;12(4):272-7. 
44. Dries S, Buis C, Adelmeijer J, et al. The combination of primary sclerosing cholangitis 
and CCR5 -Œî32 in recipi[INVESTIGATOR_75470]. Liver International 
2011;31(8):1102‚Äì09. 
45. Receptor binding properties of TAK 652, a small molecular weight CCR5 antagonist. [COMPANY_005] Chemical Industries, Ltd., Report No. TAK-652/[ZIP_CODE], Jun 2003. 
46. Preclinical testing of the CCR5/CCR2 dual antagonist Cenicriviroc (TBR -652). Study 
No. 652-9-1015 (Interim Report), [ADDRESS_81869] cenicriviroc in a mouse model of NASH. Hepatology 2013;58(S1):221A-222A. 
49. Activity of cenicriviroc in a rat model of thioacetamide -induced liver fibrosis and 
cirrhosis. Study No. 652-9-1003, 24 Dec 2013. 
50. Hong F. Chou H, Friedman SL. Significant anti- fibrotic activity of cenicriviroc, a dual 
CCR2/CCR5 antagonist, in a rat model of thioacetamide-induced liver fibrosis and cirrhosis. 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2013). Washington, DC, November 1-5, 2013. Abstract LB-7. 
51. Richards TL. Dose-dependent effects of cenicriviroc on renal biomarkers and fibrosis in unilateral ureteral occluded (UUO) mice. Study No. 652-9-1006, 28 Feb 2014. 
52. Krenkel O, Mossanen JC, Ergen C, et al. CCR2+ infiltrating monocytes promote acetaminophen -induced acute liver injury - therapeutic implications of inhibiting CCR2 
and CCL2. J Hepatol. 2015;62:S206. 
Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 68 of 82 
Amendment 3  
 
 
CONFIDENTIAL    14 June2016  53. Krenkel O, P√ºngel T, Mossanen J, e t al. Dual CCR2/CCR5 anatagonist cenicriviroc leads 
to potent and significant reduction in proinflammatory CCR2+ monocyte infiltration in 
experimental acute liver injury. Presented at: The Liver Meeting¬Æ; Nov 17, 2015; San 
Francisco, CA, [LOCATION_003]  
54. Prophylactic E ffects of Cenicriviroc on Bile Duct Ligation Induced Liver Injury and 
Hepatic Fibrosis; Study number 652-9-1030, Plato Biosciences, Tobira study report, October 2015. 
55. Cenicriviroc Mesylate. CVC (TBR -652) For the Treatment of Non Alcoholic 
Steatohepatitis ( NASH) in Subjects with Liver Fibrosis, Investigator‚Äôs Brochure, Edition 
1. Tobira Therapeutics, Inc., dated [ADDRESS_81870] 2014. 
56. Cai Z, Christianson AM, Stahle L, et al . Reexamining transaminase elevation in Phase I 
clinical trials: the importance of Baseline an d change from Baseline. Eur J Clin 
Pharmacol. 2009:65:1025-35. 
57. Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011;203:780‚Äì90. 
58. Sandler NG, Koh C, Roque A, et al. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterol. 2011;141:1220-30. 
59. Ogawa Y, Imajo K, Yoneda M, et al. Soluble CD14 Levels Reflect Liver Inflammation in Patients with Nonalcoholic  Steatohepatitis.  PLoS ONE 2013;8(6):e65211. 
doi:10.1371/journal.pone.0065211. 
60. Harte A, da Silva N, Creely S, et al. Elevated endotoxin levels in non- alcoholic fatty liver 
disease. J Inflamm .2010;7:15-24. 
61. He H, Mennone A, Boyer JL, and Cai SY. Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct ligated rats and human hepatic cells. Hepatology. 2011;53(2): 548‚Äì557. 
62. Fickert P, Pollheimer MJ, Beuers U, et al. Characterization of animal models for primary sclerosing cholangitis (PSC). J He patol. 2014;60(6):1290-303. 
63. Liedtke C, Luedde T, Sauerbruch T, et al. Experimental liver fibrosis research: update on animal models, legal issues and translational aspects. Fibrogenesis Tissue Repair. 2013;6:19. 
64. FDA Guidance for Industry. Drug- Induced Live r Injury: Premarketing Clinical 
Evaluation. July 2009. Available at http://www.fda.gov/downloads/Drugs/.../Guidances/UCM174090.pdf 
  
7RELUD7KHUDSHXWLFV,QF &HQLFULYLURF
&OLQLFDO6WXG\3URWRFRO  3DJHRI$PHQGPHQW
&21),'(17,$/  -XQH
,19(67,*$725¬∂66,*1$785(3$*(
3(56(86$3KDVH3URRIRI&RQ FHSW6WXG\,QYHVWLJDWLQJWKH3UH OLPLQDU\(IILFDF\
DQG6DIHW\RI&HQLFULYLURFLQ$ GXOW6XEMHFWVZLWK3ULPDU\6FOHU RVLQJ&KRODQJLWLV36&

3URWRFRO,VVXH'DWH -XQH
$PHQGPHQW
,KDYHUHDGXQGHUVWDQGDQGDJUHH WRIROORZWKHDWWDFKHGYHUVL RQFLWHGDERYHRI3URWRFRO

3ULQFLSDO,QYHVWLJDWRU1DPH3ULQW 6LJQDWXUH
'DWH 6LWH1XPEHU

7RELUD7KHUDSHXWLFV,QF &HQLFULYLURF
&OLQLFDO6WXG\3URWRFRO  3DJHRI$PHQGPHQW
&21),'(17,$/  -XQH
$33(1',&(6
Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 72 of 82 
Amendment 3  
CONFIDENTIAL   14 June 2016  20.1 Schedule of Assessments  

Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 73 of 82 
Amendment 3  
 
CONFIDENTIAL   14 June 2016  

Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 74 of 82 
Amendment 3  
 
CONFIDENTIAL   14 June 2016 
  
20.2 National Cancer Institute Commo n Terminology Criteria for Adverse Events (NCI 
CTCAE)  
Version 4.0 Published: May 28, 2009 (v4.03: June 14, 2010)  
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf 
Quick Reference 
The National Cancer Institute Common Terminology Criteria for Adverse Events  (NCI CTCAE)  is a 
descriptive terminology which can be utilized for AE reporting. A grading (severity) scale is provided 
for each AE term.  
Components and Organization 
System Organ Class  
System Organ Class  (SOC), the highest level of the MedDRA hierarchy, is identified by [CONTACT_75492], etiology, or purpose (e.g. , SOC investigations for laboratory test results). 
CTCAE terms are grouped by [CONTACT_75493]. Within each SOC, AEs are listed and 
accompanied by [CONTACT_75494] (grade).  
CTCAE Terms  
An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, 
or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure. An AE is a term that is a unique representation of a specific event used for medical documentation and scientific analyses. Each CTCAE v4.[ADDRESS_81871] level term ( LLT). 
Definitions  
A brief defini tion is provided to clarify the meaning of each AE term.  
Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 75 of 82 
Amendment 3  
 
CONFIDENTIAL   14 June 2016 
 Grades 
Grade refers to the severity of the AE. The CTCAE displays Grades 1 through 5 with unique clinical 
descriptions of severity for each AE based on this general guideline:  
Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated. 
Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age -
appropriate instrumental ADL*. 
Grade 3 Severe or medically significant but not immediately life -threatening; 
hospi[INVESTIGATOR_3111]; disabling; limiting self 
care ADL**.  
Grade 4 Life-threatening consequences; urgent intervention indicated  
Grade 5 Death related to AE.  
 
A semi-colon indica tes ‚Äòor‚Äô within the description of the grade.  
A single dash ( -) indicates a grade is not available.  
Not all grades are appropriate for all AEs. Therefore, some AEs are listed with fewer than  5 options 
for grade selection.  
Grade 5 (Death) is not appropriate for some AEs and therefore is not an option. 
Activities of Daily Living (ADL)  
*Instrumental ADL refer to preparing meals,  shoppi[INVESTIGATOR_3112], using the telephone, 
managing money, etc. **Self-care ADL refer to bathing, dres sing and undressing, feeding self, using the toilet, taking 
medications, and not bedridden.   
Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-[ADDRESS_81872] been determined to be more than 99% effective (failure rate < 1% per 
year, when used consistently and correctly) (Trussell 2004) and are permitted under this protocol: 
‚Ä¢ Complete abstinence from sexual intercourse if this is the subject‚Äôs usual and  preferred lifestyle  
‚Ä¢ Dual method of contraception: 
o Condom with spermicide in  conjunction with use of an intrauterine device  
o Condom with spermicide in conjunction with use of a diaphragm 
o Condom with birth control patch or vaginal ring* 
o Condom with oral, injectab le, or implanted contraceptives* 
‚Ä¢ Tubal ligation or vasectomy (surgical sterilization* *) 
* Note: Subjects who are using hormonal contraceptives should be instructed to use an additional 
contraceptive measure during the study (see above for other methods). 
** Note: For the purpose for this study protocol, ‚Äúsurgical sterilization‚Äù also includes hysterectomy 
and/or bilateral oophorectomy. 
 
Trussell J. Contraceptive failure in the [LOCATION_002]. Contraception 2004;70:89-96. 
  
Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-[ADDRESS_81873] not take the following disallowed medications at any time during the study , from 
Screening through the 4- Week Follow-up visit.   
 
 
 
 
 
 
 
 
 
 
 
  

Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 78 of 82 
Amendment 3  
 
CONFIDENTIAL   14 June 2016 
 

Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 79 of 82 
Amendment 3  
 
CONFIDENTIAL   14 June 2016 
  

Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 80 of 82 
Amendment 3  
 
CONFIDENTIAL   14 June 2016 
  
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
 
  
 
 
 
   
  
 
 
  
 
 
 
 
 
 
 
 
  
 
  
 
 
  
 
 
 
 
20.5 Clinical Laboratory Tests  
 
 
 

Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 81 of 82 
Amendment 3  
 
CONFIDENTIAL   14 June 2016 
  
 
 
 
 
 
 
 
 
  
  
 
  
 
  
  
  
  
  
 
 
 
  
  
  
  
  
   
 
   
 
 
 
  
  
  
   
   
 
 
 
 
 
 
  
 
 
 
 
 
  
 
  
  
 
 
 
 
 
  
 
 
  
 
 
 
 
   
    
  
 
 
 

Tobira Therapeutics, Inc.  Cenicriviroc  
Clinical Study Protocol 652-205  Page 82 of 82 
Amendment 3  
 
CONFIDENTIAL   14 June 2016 
 Adiponectin   

Clinical Protocol 652-205 
Amendment 3: 14 June 2016   Tobira Therapeutics  
   
Confidential  Page 1 of 2 PROTOCOL AMENDMENT 3  SUMMARY OF CHANGES   
1. Major changes  
‚Ä¢ Removal of pre- Baseline visit.  Subjects diagnosed with PSC often have elevated but 
fluctuating liver enzymes (AST, ALT, Total Bilirubin and Direct Bilirubin).  
Repeating liver enzymes at the pre- Baseline visit, and taking the average value of the 
Screening and pre- Baseline values for inclusion, has proven prohibitive in subject 
enrollment due to these normal fluctuations.  Subjects with evidence of cirrhosis or 
hepatic impairment will be excluded by [CONTACT_73429] 9. With the removal of 
the pre-Baseline visit, the mean values of the AST, ALT, Total Bilirubin and Direct 
Bilirubin parameters no longer apply, and are revised in exclusion criteri a 13 and 14. 
‚Ä¢ The upper cut- off values of Total Bilirubin and Direct Bilirubin have been changed 
to: 
o Total Bilirubin > 2.0 mg/dL 
o Direct Bilirubin > 0.8 mg/dL  
‚Ä¢ Removal of Week 2 visit. Frequent site visits negatively impacts on s ubjects‚Äô 
willingness to participate in this [ADDRESS_81874] 4 months, then 2 months later at Month 6 (end of 
treatment period). Based on safety data from other CVC studies, where subjects have 
been treated for one year, there is no safety impact with the removal of the Week 2 visit.  
‚Ä¢ Revision of inclusion criterion 3 to allow subjects without inflammatory bowel 
disease (IBD) to be eligible for the study. There is no impact on safety by [CONTACT_75495].  
‚Ä¢ Revision of inclusion criterion 5 to allow serum ALP ‚â• 1.[ADDRESS_81875], rather than only greater than,  for study entry .  
2. Administrative changes  
‚Ä¢ Updated version date throughout protocol amendment 3. 
‚Ä¢  
 
‚Ä¢ Plasma PK samples will not be drawn at Week 2 . 
‚Ä¢ Updated Section 9.3 Prior and Concomitant Therapy medication to allow the use of 
   
‚Ä¢ Updated Section 9.4 Additional Restrictions and Precautions stating results from additional studies indicating that CVC did not demonstrate phototoxic potential in 
neutral red uptake phototoxicity.  
  

Clinical Protocol 652-205 
Amendment 3: 14 June 2016   Tobira Therapeutics  
   
Confidential  Page 2 of 2 ‚Ä¢  
 
‚Ä¢  
‚Ä¢ Updated S  
  
  
  
 

Tobira Therapeutics, Inc.  Cenicriviroc 
Clinical Study Protocol 652- 205  Page 1 of 2 
CONFIDENTIAL   06 April 2016  
 
 
 
SUMMARY OF CHANGES 
 
 
 
Title: A Phase 2 Proof of Concept Study Investigating the 
Preliminary Efficacy and Safety of Cenicriviroc in Adult 
Subjects with Primary Sclerosing Cholangitis (PSC) 
 
 
Protocol Number: [ADDRESS_81876]: Cenicriviroc Mesylate (CVC) 
 
 
Phase of Study: Phase 2 
 
 
Sponsor: Tobira Therapeutics, Inc. 
 [ADDRESS_81877] 
 South San Francisco, CA [ZIP_CODE] 
 [LOCATION_002] of America 
 
 
Date of Original Protocol: 19 November 2015 
Date of Amendment 1.1: 29 December 2015 
Date of Amendment 2: 0 6 April, 2016 
 
 
 
 
 
 
 
The information in this document is privileged and confidential. No part of this information may be duplicated, 
referenced, or transmitted in any form or by [CONTACT_61076] (electronic, mechanical, photocopy, recording, or otherwise) 
without the prior written consent of Tobira Therapeutics.  

Tobira Therapeutics, Inc.  Cenicriviroc 
Clinical Study Protocol 652- 205  Page 2 of 2 
CONFIDENTIAL   06 April 2016 Summary of Changes for Protocol 652-205: PERSEUS 
The 
most noteworthy changes for Study 652-205, Amendment [ADDRESS_81878] been made for clarity. A redline version of the protocol has been provided for comparison from 
Amendment 1.1 to Amendment 2 .0.   
ÔÇ∑  
  
ÔÇ∑ Added clarification that if subjects are deemed eligible (based on their Pre-Baseline results), the Baseline visit can 
take place immediately or approximately within 2 weeks prior to the Baseline visit 
ÔÇ∑  
ÔÇ∑  
ÔÇ∑ INR was added for every visit 
ÔÇ∑ Clarified if the subjects do not fast, subjects will need to return to the center in the afternoon (approximately 6 hours 
later) for his/her fasting blood draw or the visit may be rescheduled within 72 hours 
ÔÇ∑ Added clarification on replacing subjects. If subjects discontinue from the study for reasons other than safety, 
replacement subjects will be considered. 
ÔÇ∑ The ‚ÄúSpecial Situations Report‚Äù Section has been deleted (Previously in Section [IP_ADDRESS]). This section was 
inadvertently included in the original protocol. However, for the purpose of this study, reports of medication error, 
abuse, misuse, or overdose, and reports of adverse reactions associated with product complaints will be reported to 
Tobira and  for investigation and reporting. Any corrective action items will be followed through with the 
investigators, as appropriate. Clarified the language referring to guidance if any Grade 4 laboratory abnormalities or 
clinical events occur.    
ÔÇ∑ Fibrates have been excluded as they may decrease ALP and confound efficacy results 
ÔÇ∑ Clarified IgG total and IgG1 should be performed at Baseline and Week 24 
. 
 
 

Tobira Therapeutics, Inc.  Cenicriviroc 
Clinical Study Protocol 652-205  Page 1 of 18 
CONFIDENTIAL   29 December 2015  
 
 
 
SUMMARY OF CHANGES 
 
  Title: A Phase 2 Proof of Concept Study Investigating the 
Preliminary Efficacy and Safety of Cenicriviroc in Adult Subjects with Primary Sclerosing Cholangitis (PSC) 
  Protocol Number: 652-[ADDRESS_81879]: Cenicriviroc Mesylate (CVC) 
  Phase of Study: Phase 2   Sponsor: Tobira Therapeutics, Inc. 
 [ADDRESS_81880] 
 South San Francisco, CA [ZIP_CODE] 
 [LOCATION_002] of America 
  Date of Original Protocol: 19 November 2015 Date of Amendment 1.0: 29 December 2015   
  
 
  
The information in this document is privileged and confidential. No part of this information may be duplicated, 
referenced, or transmitted in any form or by [CONTACT_61076] (e lectronic, mechanical, photocopy, recording, or otherwise) 
without the prior written consent of Tobira Therapeutics. 

Tobira Therapeutics, Inc.  Cenicriviroc 
Clinical Study Protocol 652-205  Page 2 of 18 
CONFIDENTIAL   29 December 2015 
¬†Major Changes 
Section Previous Text (Original Protocol ) Revised Text (Amendment 1.0) Rationale 
Section 4 
Synopsis (Inclusion 
Criteria) 
and  Section 8.2 Inclusion 
Criteria 2. Clinical diagnosis of PSC as evident by 
[CONTACT_75496] a consistent magnetic resonance cholangiopancreatography 
(MRCP)/endoscopic retrograde 
cholangiopancreatography (ERCP) showing sclerosing cholangitis, or a liver 
biopsy taken at any time consistent with 
PSC in the absence of a documented alternative etiology for sclerosing 
cholangitis. 2. Clinical diagnosis of PSC as evident by 
[CONTACT_75496] a consistent magnetic 
resonance cholangiopancreatography (MRCP)/endoscopic retrograde 
cholangiopancreatography (ERCP) showing 
sclerosing cholangitis, or a liver biopsy taken at any time consistent with PSC in the 
absence of a documented alternative etiology 
for sclerosing cholangitis. If diagnosis of PSC was made by [CONTACT_75497], it must require 
the presence of fibro-obliterative lesions (i.e., 
onion skin lesions). Additional sentence ‚ÄúIf diagnosis of PSC was made by [CONTACT_75497], it must 
require the presence of fibro-obliterative 
lesions (onion skin lesions)‚Äù was added to ensure histological diagnosis included this morphological observation. 
Section 4 
Synopsis (Inclusion 
Criteria)  
and 
Section 8.2 Inclusion 
Criteria 3. Confirmed Inflammatory Bowel Disease (IBD)  
 3. Documented eviden ce of Inflammatory 
Bowel Disease (IBD) either by [CONTACT_75498], for ‚â•6 months. In addition, subjects will be 
required to enter the study with a Partial Mayo Risk score of 0-3, inclusively Added language to confirm IBD diagnosis, as well as severity of IBD.  
Section 4  
Synopsis (Exclusion 
Criteria)  
and  Section 8.3  Exclusion Criteria 13. Aspartate aminotransferase (AST) and 
alanine aminotransferase (ALT) > 5 √ó ULN 
 13. Aspartate aminotransferase (AST) and 
alanine aminotransferase (ALT); above the 
allowed cut-offs,
 as determined by [CONTACT_75499]-Baseline values (subjects 
who show evidence of significant worsening 
of liver transaminases on repeat measure will be excluded): 
ÔÇ∑ AST > 200 IU/L males and females  
ÔÇ∑ ALT: males > 250 IU/L and females > 200 IU/L  Added detail to ensure that patients do not have deteriorating liver function prior to enrolment 
Tobira Therapeutics, Inc.  Cenicriviroc 
Clinical Study Protocol 652-205  Page 3 of 18 
CONFIDENTIAL   29 December 2015 
¬†Section Previous Text (Original Protocol ) Revised Text (Amendment 1.0) Rationale 
Section 4  
Synopsis (Exclusion 
Criteria) 
and  Section 8.3  Exclusion Criteria 14. Bilirubin > 3 √ó ULN  14. Total Bilirubin and Direct Bilirubin; 
above the allowed cut-offs, as determined by 
[CONTACT_75500]-Baseline values (subjects who show evidence of significant worsening of bilirubin will be excluded):  
ÔÇ∑ Total Bilirubin ‚â• 1.5 mg/dL  
ÔÇ∑ Direct Bilirubin ‚â• 0.5 mg/dL Added detail to ensure that patients do not have deteriorating liver function prior to enrolment 
Figure 7-1  
Study Design 
Schematic <added a pre-baseline visit in the schematic> -14d (-2wk) Added pre baseline visit day in order to 
ensure that there is no deteriorating liver 
function on repeat testing prior to enrollment 
Tobira Therapeutics, Inc.  Cenicriviroc 
Clinical Study Protocol 652-205  Page 4 of 18 
CONFIDENTIAL   29 December 2015 
¬†Section Previous Text (Original Protocol ) Revised Text (Amendment 1.0) Rationale 
Section 10.0  
Study Procedures <New paragraphs added> Eligible subj ects will be required to complete 
a diary daily to assess stool frequency and 
blood in the stool (Partial Mayo Risk score), daily. In addition, the diary will include a 
question regarding abdominal pain in order to 
assess if the subject develops any significant increase in abdominal pain.  If a subject 
exceeds a Partial Mayo Risk score of [ADDRESS_81881] the site immediately for clinical 
assessment for their IBD.   
The principal investigator [INVESTIGATOR_75471]. As with all adverse events, any abdominal pain will be assessed for 
severity and causality by [CONTACT_75501], per Section 11.4. Added detail on patient diary which will also now include abdominal pain question 
to assess abdominal pain. The principal 
investigator [INVESTIGATOR_75472]. 
In addition, as patients are entering the 
study with a Partial Mayo Risk score of 0-
3, any patient who exceeds a score of 4, will be required to be reevaluated for their IBD. 
  
   
 
 
 
  
 
 
 
 
 
    
 
 
 

Tobira Therapeutics, Inc.  Cenicriviroc 
Clinical Study Protocol 652-205  Page 5 of 18 
CONFIDENTIAL   29 December 2015 
¬†Section Previous Text (Original Protocol ) Revised Text (Amendment 1.0) Rationale 
 
 
 
    
 
 
 
 
 
  
  
  
  
   
  
 
 
  
 
  
  
 
 
 
 
  
  
 
 
 
 
  
  
  
  
   
 
 
 
 
 
 
  
 
 
  
  
 
  
  
 
 
  
  
 
 
  
 
 
 
 
 
 
 
 
  
 

Tobira Therapeutics, Inc.  Cenicriviroc 
Clinical Study Protocol 652-205  Page 6 of 18 
CONFIDENTIAL   29 December 2015 
¬†Section Previous Text (Original Protocol ) Revised Text (Amendment 1.0) Rationale 
  
  
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
  
    
  
    
   
 
    
 
 
 
 
 
 
 
   
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
  
 
 s  
 

Tobira Therapeutics, Inc.  Cenicriviroc 
Clinical Study Protocol 652-205  Page 7 of 18 
CONFIDENTIAL   29 December 2015 
¬†Section Previous Text (Original Protocol ) Revised Text (Amendment 1.0) Rationale 
 
 
 
 
 
 
  
  
 
 
  
 
  
  
 
 
  
  
 
 
 
 
 
 
  
 
 
 
  
 
  
  
 
 
 

Tobira Therapeutics, Inc.  Cenicriviroc 
Clinical Study Protocol 652-205  Page 8 of 18 
CONFIDENTIAL   29 December 2015 
¬†Section Previous Text (Original Protocol ) Revised Text (Amendment 1.0) Rationale 
 
  
 
  
 
 
  
 
 
 
  
 
 
 
  
 
 
   
 
 
 
 
  
 
 
 
 
 
 
 
 
   
 
  
 
  
  
 
 
  
  
 
 
  
 
 
 
 
 
 
 
 

Tobira Therapeutics, Inc.  Cenicriviroc 
Clinical Study Protocol 652-205  Page 9 of 18 
CONFIDENTIAL   29 December 2015 
¬†Section Previous Text (Original Protocol ) Revised Text (Amendment 1.0) Rationale 
 
 
 
 
 
  

Tobira Therapeutics, Inc.  Cenicriviroc 
Clinical Study Protocol 652-205  Page 10 of 18 
CONFIDENTIAL   29 December 2015 
¬†Minor Changes 
Section Previous Text (Original Protocol ) Revised Text (Amendment 1.0) Rationale 
Section 4.0 
Synopsis (Study 
Design) Screening will occur within 4 weeks before the Baseline Visit (Day 1).  At Day -28 
(approximately), subjects will undergo all 
eligibility evaluations per the schedule of assessments. Screening will occur within 6 weeks before the Baseline Visit (Day 1).  At Day -42 
(approximately), subjects will undergo all 
eligibility evaluations per the schedule of assessments. A pre-Baseline visit will occur 
2 weeks (Day -14) prior to the Baseline visit 
for liver parameter testing. Screening within 4 weeks of Baseline Visit (Day 1) was updated from 4 weeks 
to 6 weeks and Day -28 was updated to -
42 because of inclusion of the pre-Baseline visit, which occurs at week -2 
(day -14)  in order to get a repeat of liver 
function parameters prior to enrollment.  
Additional sentence regarding a pre-
Baseline Visit was added as per above.  
Section 4  
Synopsis (Exclusion 
Criteria) 
and Section 8.3  Exclusion Criteria 1. Presence of documented secondary 
sclerosing cholangitis on prior clinical 
investigations  
 1. Presence of documented secondary 
sclerosing cholangitis (such as ischemic 
cholangitis, recurrent pancreatitis, intraductal 
stone disease, severe bacterial cholangitis, surgical or blunt abdo minal trauma, recurrent 
pyogenic cholangitis, choledocholithiasis, toxic slerosing cholangitis due to chemical agents, or any other cause of secondary 
sclerosing cholangitis) on prior clinical 
investigations 
 Examples of secondary sclerosing 
cholangitis have been included. 
Section 4  
Synopsis (Exclusion 
Criteria)  
and  Section 8.3  Exclusion Criteria 9. History of cirrhosis and/or hepatic 
decompensation including ascites, encephalopathy or variceal bleeding 9. History of cirrhosis and/or hepatic impairment (Child-Pugh classes A, B and C) 
and/or hepatic decompensation including 
ascites, encephalopathy or variceal bleeding. Subjects who show evidence of significant 
worsening of hepatic function will be 
excluded Added the verbiage ‚Äúimpairment (Child-Pugh classes A, B, and C) to clarify no hepatic decompensation or cirrhosis allowed.  
Tobira Therapeutics, Inc.  Cenicriviroc 
Clinical Study Protocol 652-205  Page 11 of 18 
CONFIDENTIAL   29 December 2015 
¬†Section Previous Text (Original Protocol ) Revised Text (Amendment 1.0) Rationale 
Section 4  
Synopsis (Exclusion 
Criteria) 
and  Section 8.3  Exclusion Criteria 10. Subjects with fibrosis evidence of 
cirrhosis, as determined by [CONTACT_75474] (TE; e.g., FibroScan¬Æ) values 
of ‚â• 13.[ADDRESS_81882] 6 
months. If TE has not been conducted 
within the 6 months prior to screening then 
one will be conducted during the screening period and can be used as the Baseline value 10. Subjects with evidence of cirrhosis, as 
determined by [CONTACT_75476] 
(TE; e.g., FibroScan
¬Æ) values of ‚â•  13.[ADDRESS_81883] ‚Äòfibrosis‚Äô due to typo in original version (sentence was incorrect and nonsensical). 
Section 4  
Synopsis (Exclusion 
Criteria) 
and  Section 8.[ADDRESS_81884] 90 days requiring intensification of therapy beyond 
Baseline treatment. Subjects with stable mild 
to moderate IBD, who are on treatment, are 
allowed provided they are stable for 3 
months with 5-amino salicylic acid drugs or 
Azathioprine (allowed dose of azathioprine is 50-200 m
g/day). Added  the allowable dose range for azathioprine of 50-200mg/day 
Section 4  
Synopsis (Exclusion 
Criteria) 
and  Section 8.3  Exclusion Criteria 15. International normalized ratio > 1.3 in 
the absence of anticoagulants.  
 15. International normalized ratio (INR) 
> 1.3 in the absence of anticoagulants. 
 Abbreviation ‚Äú(INR)‚Äù added as it is used 
elsewhere in the protocol 
Section 4 Synopsis (Study Procedures/Frequency) Screening will occur within 4 weeks before the Baseline Visit.  Screening will occur within 6 weeks before the Baseline Visit.  A pre-Baseline visit will occur 2 weeks before Baseline. Screening within 4 weeks of Baseline Visit (Day 1) was updated to 6 weeks. 
Additional sentence regarding a pre-
Baseline Visit was added to include a -2 
week (Day -14) visit in order to get a 
repeat of liver function parameters prior to enrollment 
Section 4 Synopsis (Study Procedures/Frequency) IgG Total, IgG1 and IgG4 will be collected at Baseline, and Week 24 IgG Total, IgG1 and IgG4 will be collected at Baseline, and Week 24 (IgG4 will also be collected at Screening) Clarification that IgG4 will also be collected at Screening 
Tobira Therapeutics, Inc.  Cenicriviroc 
Clinical Study Protocol 652-205  Page 12 of 18 
CONFIDENTIAL   29 December 2015 
¬†Section Previous Text (Original Protocol ) Revised Text (Amendment 1.0) Rationale 
Section 4 Synopsis 
(Study Procedures/Frequency) Transient elastography will be assessed once during the Screening period (between Day -28 to Baseline) and again at Week 24 Transient elastography will be assessed once during the Screening period (between Day - 42 to Baseline) and again at Week 24 Changed Day -28 to Day -42 according to new schedule 
Section 4 Synopsis (Study Procedures/Frequency) Plasma pharmacokinetic (PK) samples will be drawn pre-dose at Baseline and at Weeks 2, 12, and 24 Plasma pharmacokinetic (PK) samples will be drawn pre-dose and post-dose at Baseline and at Weeks 2, 12, and [ADDRESS_81885] been exposed to CVC, including 440 healthy subjects (of 
which 8 had mild and 8 had moderate 
hepatic impairment] and 159 HIV 1 
infected subjects) have received at least [ADDRESS_81886] been exposed to CVC in completed studies, 
including 440  subjects participating in Phase 
1 studies (of which 8 had mild and 8 had 
moderate hepatic impairment) and [ADDRESS_81887] 1 dose of CVC. Updated this section administratively 
Section 7.1  
Overall Study Design 
and Plan Screening will occur within 4 weeks before the Baseline Visit.  Screening will occur within 6 weeks before the Baseline Visit. A pre-Baseline visit for 
repeat measure of liver parameter tests will 
occur within 2 weeks before the Baseline visit. Screening within 4 weeks of Baseline Visit (Day 1) was updated to 6 weeks. 
Additional sentence regarding a pre-
Baseline Visit was added to include a -2 
week (Day -14) visit in order to get a repeat of liver function parameters prior to enrollment 
Figure 7-1  
Study Design 
Schematic -28d (-4wk) in the schematic -42d (-6wk) in the schematic Screening within 4 weeks of Baseline 
Visit (Day 1) was updated from 4 weeks 
to 6 weeks and Day -28 was updated to -
42 because to include a -2 week (Day -14) visit in order to get a repeat of liver function parameters prior to enrollment 
  
 
   
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
 

Tobira Therapeutics, Inc.  Cenicriviroc 
Clinical Study Protocol 652-205  Page 13 of 18 
CONFIDENTIAL   29 December 2015 
¬†Section Previous Text (Original Protocol ) Revised Text (Amendment 1.0) Rationale 
  
    
 
Section 10.1 Screening <Scree ning (Days -28; Visit 1> 
Prior to any clinical procedures and 
evaluations, written signed informed consent must be obtained. Screening 1 is to 
occur approximately 4 weeks (28 days) 
before the Baseline Visit (see Section 10.2). 
 <Screening (Days -42; Visit 1> Prior to any clinical procedures and 
evaluations, written signed informed consent must be obtained. Screening  is to occur 
approximately 4 weeks (28 days) before the 
pre-Baseline visit (see Section 10.2), and 6 
weeks (42 days) before the Baseline Visit 
(see Section 10.3). Screening within 4 weeks of Baseline Visit (Day 1) was updated to 6 weeks. 
Additional sentence regarding a pre-
Baseline Visit was added to include a -2 
week (Day -14) visit in order to get a 
repeat of liver function parameters prior to enrollment  
 
   
 
 
  
 
 
 
 
  
  
 
  
 
 
  
  
 
 
 
  
 
  
 
  
 
 
  
 
 
  
 
 
 

Tobira Therapeutics, Inc.  Cenicriviroc 
Clinical Study Protocol 652-205  Page 14 of 18 
CONFIDENTIAL   29 December 2015 
¬†Section Previous Text (Original Protocol ) Revised Text (Amendment 1.0) Rationale 
  
 
   
 
 
 
 
 
 
 
 
 ¬† 
 
  
  
 
   
 
 
 
 
  
   
Section 10.5  
4-Week Follow-up <section title> 
4-Week Follow-up (Week 28, Day 196; Visit 9) <section title> 4-Week Follow-up (Week 28, Day 196; Visit 10) Additional Pre-Baseline Visit included so Visit number assigned to 4-Week Follow-up is now Visit 10 instead of 
Visit 9
Section [IP_ADDRESS] 
Clinically Significant 
Laboratory 
Abnormalities Any laboratory test showing abnormal results (including those recorded as AEs) that are believed to be possibly/probably 
related to study drug treatment will be 
repeated weekly (or as often as deemed prudent by [CONTACT_093]) until the 
abnormality is resolved, returns to 
Baseline, or is otherwise explained. 
Whenever possible, the etiology of the 
abnormal findings will be documented on the CRF. See Section [IP_ADDRESS].[ADDRESS_81888] showing abnormal results (including those recorded as AEs) that are believed to be possibly/probably related to 
study drug treatment will be repeated weekly 
(or as often as deemed prudent by [CONTACT_093]) until the abnormality is 
resolved, returns to Baseline, or is otherwise 
explained. Whenever po ssible, the etiology 
of the abnormal findings will be documented on the CRF. See Section [IP_ADDRESS].6 for a definition of clinically significant laboratory 
abnormality. For management of subjects 
with elevated liver tests, please refer to Section [IP_ADDRESS].Added the last sentence to refer to section [IP_ADDRESS] 

Tobira Therapeutics, Inc.  Cenicriviroc 
Clinical Study Protocol 652-205  Page 15 of 18 
CONFIDENTIAL   29 December 2015 
¬†Section Previous Text (Original Protocol ) Revised Text (Amendment 1.0) Rationale 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
  
 
 
 
 
  
 
 

Tobira Therapeutics, Inc.  Cenicriviroc 
Clinical Study Protocol 652-205  Page 16 of 18 
CONFIDENTIAL   29 December 2015 
¬†Section Previous Text (Original Protocol ) Revised Text (Amendment 1.0) Rationale 
  
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
   
 
   
 
 
 
 
 
 
 
 
 
 
 
  
  
 
   
  
  
  
 
  
  
  
  
 
   
  
  
  
  
 
 
  
 
  
 

Tobira Therapeutics, Inc.  Cenicriviroc 
Clinical Study Protocol 652-205  Page 17 of 18 
CONFIDENTIAL   29 December 2015 
¬†Section Previous Text (Original Protocol ) Revised Text (Amendment 1.0) Rationale 
  
  
 
   
 
 
 
 
 
 
 
  
 
  
  
  
 
   
 
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
   
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
 
  
 
 
  
 

Tobira Therapeutics, Inc.  Cenicriviroc 
Clinical Study Protocol 652-205  Page 18 of 18 
CONFIDENTIAL   29 December 2015 
¬†Section Previous Text (Original Protocol ) Revised Text (Amendment 1.0) Rationale 
Section 20.5 Clinical 
Laboratory Tests Pre-dose PK Samples (for storage): Baseline and Weeks 12 and 24 
PK samples will be
 stored for analysis  and 
assessment of study drug compliance, if 
applicable PK Samples: Baseline and Weeks 2, [ADDRESS_81889] be drawn if liver function testing is repeated for abnormalities.  
 
Additional minor editorial ch anges, clarifications, and corrections are not listed. 